var data={"title":"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Jaime R Merchan, MD, MMSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Kenar D Jhaveri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 25, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of renal diseases and electrolyte disorders can result from the drugs that are used to treat malignant disease, including conventional cytotoxic agents and molecularly targeted agents, which take advantage of molecular abnormalities that have been detected in certain types of cancer. All of these drugs can affect the glomerulus, tubules, interstitium, or renal microvasculature, with clinical manifestations that range from an asymptomatic elevation of serum creatinine and electrolyte disorders to acute kidney injury requiring dialysis. </p><p>The kidneys are a major elimination pathway for many antineoplastic drugs and their metabolites, and renal impairment can result in delayed drug excretion and metabolism of chemotherapeutic agents, and increased systemic toxicity. Many drugs require dose adjustment when administered in the setting of renal insufficiency (<a href=\"image.htm?imageKey=ONC%2F56245\" class=\"graphic graphic_table graphicRef56245 \">table 1</a>). Minimizing nonrenal systemic toxicity may be a particular problem in patients on chronic hemodialysis, especially when the details of drug elimination and metabolism are not fully known. </p><p>The nephrotoxicity of conventional cytotoxic chemotherapy agents, preventive strategies, and recommended dose modifications in patients with renal insufficiency will be reviewed here. Renal toxicities seen with several classes of molecularly targeted and biologic agents, renal toxicity associated with drugs that target the vascular endothelial growth factor pathway, immune-mediated renal toxicity associated with checkpoint inhibitor immunotherapy (ie, <a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>, <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a>, <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a>), an overview of renal diseases associated with various cancers (including paraneoplastic syndromes), and the renal complications of tumor lysis syndrome and hematopoietic cell transplantation are discussed elsewhere. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents&quot;</a> and <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects#H1651225341\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;, section on 'Proteinuria/nephrotic syndrome'</a> and <a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy#H645724\" class=\"medical medical_review\">&quot;Toxicities associated with checkpoint inhibitor immunotherapy&quot;, section on 'Kidney'</a> and <a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient\" class=\"medical medical_review\">&quot;Overview of kidney disease in the cancer patient&quot;</a> and <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;</a> and <a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Kidney disease following hematopoietic cell transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ESTIMATION OF GFR FOR POSSIBLE DOSE ADJUSTMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are two principal pathways for drug excretion by the kidney: glomerular filtration and tubular secretion. Glomerular filtration plays a major role with non-protein-bound small molecules (ie, of a size that can pass through the glomerular capillary wall). Such molecules cannot be filtered if they are protein bound in the circulation; these drugs, if they are renally excreted, enter the urine by secretion in the proximal tubule.</p><p>For those drugs in which renal excretion is an important determinant of elimination of the intact drug or an active metabolite, dose adjustment is often required if renal function is impaired. Although the prevalence of an elevated serum creatinine is low in cancer patients (&lt;10 percent), the prevalence of a reduced glomerular filtration rate (GFR) is relatively high (50 to 53 percent in two cohort studies [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/1,2\" class=\"abstract_t\">1,2</a>]).</p><p>For most chemotherapeutic drugs (with the exception of high-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>), measurement of serum drug concentrations is not usually performed. (See <a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate#H32\" class=\"medical medical_review\">&quot;Therapeutic use and toxicity of high-dose methotrexate&quot;, section on 'Laboratory monitoring during treatment'</a>.)</p><p>Dose adjustment in this setting is typically based upon two factors: an estimation of GFR, which serves as an index of the number of functioning nephrons, and evaluation of clinical signs of drug toxicity (eg, neutropenia, thrombocytopenia). Clinicians should use the method to estimate GFR that provides the most accurate assessment of GFR [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/3,4\" class=\"abstract_t\">3,4</a>]. A creatinine clearance (CrCl) calculation based upon a 24-hour collection of urine is cumbersome and subject to error due to incomplete urine collection. Estimation equations (eg, Cockcroft-Gault (<a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years\" class=\"calc calc_professional\">calculator 1</a> and <a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years-si-units\" class=\"calc calc_professional\">calculator 2</a>), Modification of Diet in Renal Disease [MDRD] (<a href=\"topic.htm?path=calculator-glomerular-filtration-rate-estimate-by-abbreviated-mdrd-study-equation-in-adults\" class=\"calc calc_professional\">calculator 3</a>), and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] (<a href=\"topic.htm?path=calculator-glomerular-filtration-rate-estimate-by-ckd-epi-equation-in-adults\" class=\"calc calc_professional\">calculator 4</a>)) based upon a stable serum creatinine concentration also correlate with the measured GFR. They are now the most common methods used in routine clinical practice, due primarily to convenience. The available data in cancer patients suggest that all bedside formulae provide similar levels of concordance in estimation of GFR for the purpose of dosing renally excreted cancer drugs [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/5\" class=\"abstract_t\">5</a>]. These issues are discussed in detail elsewhere. (See <a href=\"topic.htm?path=assessment-of-kidney-function#H20659769\" class=\"medical medical_review\">&quot;Assessment of kidney function&quot;, section on 'Estimation equations'</a>.)</p><p>Of note, a point-of-care device for measuring serum creatinine (the i-STAT system, used for routine testing in some clinical laboratories) can give a falsely elevated creatinine measurement in patients receiving <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/6\" class=\"abstract_t\">6</a>]. In such cases, a method of creatinine measurement other than i-STAT should be used. (See <a href=\"#H935841151\" class=\"local\">'Hydroxyurea'</a> below.)</p><p>Determining the appropriate dosing of a drug that is eliminated even partially by the kidneys according to the estimated GFR requires reference to evidence-based recommendations. Proposed guidelines for dose adjustment of antineoplastic drugs according to CrCl are available from several groups [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/1,7,8\" class=\"abstract_t\">1,7,8</a>]. When known, dosing guidelines for individual drugs in patients with chronic kidney disease (and those undergoing dialysis) are available through the Lexicomp drug database within UpToDate and are summarized in the sections below.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">RISK FACTORS FOR NEPHROTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several factors can potentiate renal dysfunction and contribute to the nephrotoxic potential of antineoplastic drugs. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravascular volume depletion, either due to external losses or fluid sequestration (as in ascites or edema). This is one of the most common factors contributing to the nephrotoxic potential of antineoplastic drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The concomitant use of nonchemotherapeutic nephrotoxic drugs (eg, aminoglycoside antibiotics, nonsteroidal antiinflammatory agents, and proton pump inhibitors) or radiographic ionic contrast media in patients with or without preexisting renal dysfunction. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-contrast-induced-nephropathy\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urinary tract obstruction secondary to the underlying tumor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intrinsic renal disease that is idiopathic, related to other comorbidities, age related, or related to the cancer itself. (See <a href=\"topic.htm?path=the-aging-kidney\" class=\"medical medical_review\">&quot;The aging kidney&quot;</a> and <a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient\" class=\"medical medical_review\">&quot;Overview of kidney disease in the cancer patient&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H263265423\"><span class=\"h1\">DRUG HANDLING IN DIALYSIS PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Minimizing nonrenal systemic toxicity in patients receiving chemotherapy may be a particular problem in patients on chronic hemodialysis, especially when the details of drug elimination and metabolism are not fully known [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/9\" class=\"abstract_t\">9</a>]. For patients undergoing dialysis, two issues must be considered:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Since the kidneys are no longer functioning, dose reduction may be needed to avoid overexposure and drug toxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug clearance by dialysis must be taken into account for appropriate timing of chemotherapy in patients treated with hemodialysis.</p><p/><p>For those drugs in which a substantial fraction is removed by hemodialysis, chemotherapy should be administered after dialysis to avoid drug removal and loss of efficacy. On the other hand, for drugs that are not significantly removed by dialysis, administration is not related to the timing of dialysis.</p><p>Partial dialysis removal may be used to improve drug tolerance. As an example, dialysis sessions may be started at a certain time following administration of a drug such as <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> to remove the drug that has not been distributed to its site of action but may still contribute to side effects.</p><p>Data on management of cytotoxic chemotherapy drugs and combination regimens in patients undergoing dialysis are scant and consist mainly of single case reports. Proposed guidelines for dose adjustment and timing of cytotoxic drug administration in patients undergoing hemodialysis are available from several groups [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/1,7,10\" class=\"abstract_t\">1,7,10</a>]. When known, dosing guidelines for individual drugs in patients undergoing dialysis are available through the Lexicomp drug database in UpToDate.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">ALKYLATING AGENTS</span></p><p class=\"headingAnchor\" id=\"H10242529\"><span class=\"h2\">Bendamustine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=bendamustine-drug-information\" class=\"drug drug_general\">Bendamustine</a> is an alkylating agent that is used for treatment of chronic lymphocytic leukemia and indolent B cell non-Hodgkin lymphoma. Moderate renal impairment (creatine clearance [CrCl] 40 to 80 <span class=\"nowrap\">mL/min)</span> does not appear to alter the pharmacokinetics [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/11\" class=\"abstract_t\">11</a>]. For patients with CrCl &lt;40 <span class=\"nowrap\">mL/min,</span> limited data suggest that grade 3 or 4 treatment-related toxicity is more frequent [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/12\" class=\"abstract_t\">12</a>]. The <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826&amp;token=11bADw5mEhpo8wrO8mMj+hLgwpj3RyLkkeuyYdsVPtc8jDlrX3mhslTM6e52+4BEFsaTeBijX+WL51FNS78M1TKVdkOlB5Hg0UPjgtM7AygpKTFixmlbETflTgopufGR&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for one bendamustine product (Treanda) recommends that bendamustine not be used in patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span>. Similar guidance is available from <a href=\"http://cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=cwKQPBf82ZZ/5UV3xF0/paNI/YvDK55qAyNodbgRAqvGWFidMLlsyQOTR+4kjyfJibLxkSIOc5EX2AwdfAJaZoFYhcDtKgAISSk+2IOEu5k=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf&amp;token=pN/YFzoXlbjLw9+CIpSdc2EC4+KrQU/DW7kkOFLQ7JibCa75+N4jLylEUZe91r56jF+VHWwNvlMaL6pblMvvH4WLG/cD1ix3SxvtK1HIHWyzzkw0HX6hkTvPMepsIbUh&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for a second marketed bendamustine product (Bendeka) recommends that the drug not be administered for CrCl &lt;40 <span class=\"nowrap\">mL/min</span>.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Cyclophosphamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main urologic toxicity of <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> is hemorrhagic cystitis. The primary renal effect of cyclophosphamide is hyponatremia, which is due to an increased effect of antidiuretic hormone (syndrome of inappropriate antidiuretic hormone secretion [SIADH]) impairing the kidney's ability to excrete water [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/13-15\" class=\"abstract_t\">13-15</a>]. Chemotherapy-induced nausea may also play a contributory role since nausea is a potent stimulus to antidiuretic hormone release. (See <a href=\"topic.htm?path=cystitis-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Cystitis in patients with cancer&quot;</a> and <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p>Hyponatremia is usually seen in patients receiving high doses of intravenous (IV) <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> (eg, 30 to 50 <span class=\"nowrap\">mg/kg</span> or 6 <span class=\"nowrap\">g/m<sup>2</sup></span> in the setting of hematopoietic stem cell transplantation). Although less common, hyponatremia can also occur with oral therapy or with lower IV doses (eg, 10 to 15 <span class=\"nowrap\">mg/kg)</span> given as pulse therapy in autoimmune diseases such as lupus nephritis. (See <a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Kidney disease following hematopoietic cell transplantation&quot;</a>.)</p><p>Hyponatremia typically occurs acutely and resolves within approximately 24 hours after discontinuation of the drug. Hyponatremia poses a particular problem for patients undergoing high-dose IV <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, who are often fluid loaded to prevent hemorrhagic cystitis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/15\" class=\"abstract_t\">15</a>]. The combination of increased antidiuretic hormone effect and enhanced water intake can lead to severe, occasionally fatal hyponatremia within 24 hours. This complication can be minimized by using isotonic saline rather than hypotonic solutions to maintain a high urine output. However, hyponatremia can worsen even with isotonic saline administration. (See <a href=\"topic.htm?path=treatment-of-hyponatremia-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh-and-reset-osmostat#H3\" class=\"medical medical_review\">&quot;Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat&quot;, section on 'Therapies to raise the serum sodium'</a>.)</p><p>The need for <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> dose reduction in patients with preexisting renal insufficiency is controversial. </p><p>Dose adjustment is not recommended by several authors citing the lack of association between renal function and either <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> clearance or hematologic toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16,17\" class=\"abstract_t\">16,17</a>]. On the other hand, others suggest the need for dose adjustment based upon the altered pharmacokinetics in renal insufficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/18\" class=\"abstract_t\">18</a>]. Not surprisingly, the recommendations from expert groups are variable: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cef038cc-efab-46d9-99c2-95bb11d6c9bc&amp;token=lg2YpDlc1VLcL3AUw7yI2cDfqeX+83Cgw4gcD7rvI1lS/jogFP+9pCB2foTf/7+/g8YiaiYBTTTL2msfQ6yKQIoRR5Q/whHkQn71PDPkDkppQz+dVYPHU3UYgy/lfW5A&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> states that patients with severe renal impairment (CrCl = 10 <span class=\"nowrap\">mL/min</span> to 24 <span class=\"nowrap\">mL/min)</span> are at risk for decreased renal excretion and higher plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity. They do not recommend a specific dose reduction, but do recommend that such patients be closely monitored for signs and symptoms of toxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some authors advocate a 25 percent dose reduction in patients with CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>], while others have suggested only a 10 and 20 percent dose reduction for patients with CrCl values less than 55 and 20 <span class=\"nowrap\">mL/min,</span> respectively [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> for management of patients receiving <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> suggest a 25 percent reduction in dose in patients with CrCl &lt;50 <span class=\"nowrap\">mL/min</span> and use of extreme caution or drug discontinuation for CrCl &lt;10 <span class=\"nowrap\">mL/min</span>.</p><p/><p>In patients with end-stage renal disease (ESRD), <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> is moderately hemodialyzable; it should be administered after hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,10,20\" class=\"abstract_t\">8,10,20</a>]. In patients on peritoneal dialysis, some authors suggest a 25 percent dose reduction [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"topic.htm?path=drug-removal-in-continuous-renal-replacement-therapy\" class=\"medical medical_review\">&quot;Drug removal in continuous renal replacement therapy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Ifosfamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Similar to <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, the predominant toxicity of <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> on the urinary tract is hemorrhagic cystitis. Ifosfamide can also cause SIADH. (See <a href=\"topic.htm?path=cystitis-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Cystitis in patients with cancer&quot;</a> and <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p>However, nephrotoxicity is more likely with <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> than with <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>. Ifosfamide nephrotoxicity affects the proximal tubule and is characterized by one or more of the following signs of acute tubular dysfunction:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metabolic acidosis with a normal anion gap (hyperchloremic acidosis) due to type 1 (distal) or type 2 (proximal) renal tubular acidosis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypophosphatemia induced by decreased proximal phosphate reabsorption, which can lead to rickets in children</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Renal glucosuria, aminoaciduria, and a marked increase in beta-2-microglobulin excretion, all from generalized proximal dysfunction</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polyuria due to nephrogenic diabetes insipidus</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypokalemia, which may be severe, resulting from increased urinary potassium losses</p><p/><p>These data on tubular dysfunction come predominantly from pediatric patients treated with <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a>. There are few data on long-term renal function in adults who have received ifosfamide. However, a persistent decline in glomerular filtration rate (GFR) over time has been described after as little as one course of ifosfamide in adults [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/21\" class=\"abstract_t\">21</a>]. Nephrotoxicity due to ifosfamide is discussed in detail elsewhere. (See <a href=\"topic.htm?path=ifosfamide-nephrotoxicity\" class=\"medical medical_review\">&quot;Ifosfamide nephrotoxicity&quot;</a>.)</p><p>Preexisting renal disease is a risk factor for <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> nephrotoxicity. Guidelines for dose reduction based upon renal function are available from expert groups, although they differ markedly:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91e433a9-6800-43a6-ac13-a49a04a5aecd&amp;token=0FRFJ8vPVZvNrnM/yP44oa+LYppkRYU7tAYgZnYsCctb96CmLSMWniT6hWbRFc4wietB6fTmrqxpT10LljJHEBg79AUPd/DqqSphFtqjOIyzWNOWhDkBg7/rxnIa9NtK&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> does not contain specific dose adjustment guidelines, citing the lack of formal studies conducted in patients with renal impairment. However, patients with renal impairment should be closely monitored for toxicity, with consideration of dose reduction. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kintzel suggests the following [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"abstract_t\">16</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 46 to 60 <span class=\"nowrap\">mL/min</span> &ndash; 20 percent dose reduction</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 31 to 45 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl &lt;30 <span class=\"nowrap\">mL/min</span> &ndash; 30 percent dose reduction</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast, Aronoff suggests reducing the dose by 25 percent only in patients with CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Others suggest a 25 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend a 25 percent dose reduction for CrCl 40 to 60 <span class=\"nowrap\">mL/min,</span> a 50 percent dose reduction for CrCl 20 to 40 <span class=\"nowrap\">mL/min,</span> and that the drug be discontinued for CrCl &lt;10 <span class=\"nowrap\">mL/min</span>. </p><p/><p><a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">Ifosfamide</a> is dialyzable, and it should be administered after hemodialysis with a 50 percent dose reduction [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22,23\" class=\"abstract_t\">22,23</a>]. A 50 percent dose reduction is also suggested for patients on peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H2899775478\"><span class=\"h2\">Melphalan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">Melphalan</a> is an alkylating agent that is used mainly for the treatment of multiple myeloma. Melphalan has been associated with the development of SIADH [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/24,25\" class=\"abstract_t\">24,25</a>]. (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p>Although the drug is mostly metabolized by the liver, 10 to 30 percent is excreted unchanged in the urine. </p><p>Recommendations from expert groups for dose reduction in the setting of renal insufficiency differ:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1922268b-f093-4a35-8549-8450d4660921&amp;token=IH89kNWRI9ygnv00HGMGKwd0DebCvx4zoRKBEkizC/PJrQ+diWNxLKyBbwrR9fqLr4qGLz1qAdXK5+NGYHXQN2LkrI8BbUwoVZJCli9gWAmGK3Hv3vMtULjK7LaQ56fF&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for IV <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> suggests a 50 percent dose reduction in patients with renal insufficiency (defined only as a blood urea nitrogen [BUN] &ge;30 <span class=\"nowrap\">mg/dL)</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Others recommend that the dose of IV <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> used as a conditioning regimen for hematopoietic cell transplantation be reduced from 200 to 140 <span class=\"nowrap\">mg/m<sup>2</sup></span> in patients with serum creatinine &gt;2.0 <span class=\"nowrap\">mg/dL</span> (177 <span class=\"nowrap\">micromol/L)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another guideline recommends a 25 percent dose reduction in IV <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff recommends the following dose modification for oral <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction.</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl &lt;10 <span class=\"nowrap\">mL/min</span> &ndash; 50 percent dose reduction.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other clinicians recommend a 25 percent dose reduction for <strong>oral</strong> <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> in patients with multiple myeloma and a serum creatinine concentration above 2 <span class=\"nowrap\">mg/dL</span> (177 <span class=\"nowrap\">micromol/L)</span> to prevent severe myelotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another guideline recommends a decrease in the initial oral <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> dose from 6 mg once daily to 4 mg once daily in patients with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a decrease in dose from 6 mg daily to 3 mg daily in those with CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend dose reduction for both oral and IV <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> as follows:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl &lt;10 <span class=\"nowrap\">mL/min</span> &ndash; 50 percent dose reduction </p><p/><p><a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">Melphalan</a> is dialyzable. Some recommend administering one-half of the usual dose after dialysis in patients undergoing hemodialysis and in those undergoing peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>]. Experience with high-dose IV melphalan in patients on dialysis is limited [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Nitrosoureas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A slowly progressive, chronic interstitial nephritis that is generally irreversible can be induced by prolonged therapy with the nitrosoureas <a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">carmustine</a> (BiCNU), <a href=\"topic.htm?path=lomustine-drug-information\" class=\"drug drug_general\">lomustine</a> (CCNU), and <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Although the exact mechanism of nephrotoxicity is not completely elucidated, these agents may produce nephrotoxicity through alkylation of tubular cell proteins. Their metabolites, which are thought to be responsible for nephrotoxicity, persist in the urine for up to 72 hours following administration [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Although the primary dose-limiting toxicity of <a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">carmustine</a> is pulmonary injury, it has been associated with renal insufficiency in several reports [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/32\" class=\"abstract_t\">32</a>]. Histologic changes include mild interstitial infiltrates and tubular changes. (See <a href=\"topic.htm?path=nitrosourea-induced-pulmonary-injury\" class=\"medical medical_review\">&quot;Nitrosourea-induced pulmonary injury&quot;</a>.)</p><p><a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">Streptozocin</a>, a nonmyelosuppressive nitrosourea, has been associated with nephrotoxicity in up to 75 percent of patients treated for prolonged periods of time. Although nephrotoxicity is not necessarily dose related, it is rare in patients treated with &lt;1 to 1.5 <span class=\"nowrap\">g/m<sup>2</sup></span> per week [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/33\" class=\"abstract_t\">33</a>]. Streptozocin damages the renal tubules, causing atrophy and tubulointerstitial nephritis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/34\" class=\"abstract_t\">34</a>]; other case reports describe uric acid nephrolithiasis and acute kidney injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/35\" class=\"abstract_t\">35</a>], and diabetes insipidus [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/36\" class=\"abstract_t\">36</a>] following streptozocin.</p><p>Mild proteinuria or an asymptomatic elevation in the plasma creatinine concentration is usually the first sign of renal involvement, followed by signs of proximal tubular damage (eg, phosphaturia, glycosuria, aminoaciduria, uricosuria, and bicarbonaturia). In one study of 52 patients treated for advanced islet cell carcinoma, the most common sign of nephrotoxicity was proteinuria (51 percent), followed by renal tubular acidosis (17 percent), Fanconi syndrome (13 percent), and azotemia (26 percent) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/37\" class=\"abstract_t\">37</a>]. Nephrotoxicity contributed to death in 11 percent of treated patients.</p><p>The onset of clinical nephrotoxicity may be delayed from several months to as long as several years after nitrosoureas have been discontinued. As a result, careful long-term follow-up is essential. If it develops, nephrotoxicity typically persists for approximately two to three weeks after the drug is stopped. There is no known therapy for this disorder once it has begun. It has been suggested, however, that the nephrotoxicity can be diminished by the use of forced diuresis (2 liters of isotonic saline per hour for two hours) when the drug is being given [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Little published information is available to guide dosing of nitrosoureas in patients with renal impairment. The United States prescribing information does not contain dosing adjustments for any of these drugs in the setting of preexisting renal insufficiency. </p><p>Guidelines are available from several groups, although they differ:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff recommends the following modification scheme for <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a> and <a href=\"topic.htm?path=lomustine-drug-information\" class=\"drug drug_general\">lomustine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl &lt;10 <span class=\"nowrap\">mL/min</span> &ndash; 50 to 75 percent dose reduction</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend:</p><p/><p class=\"bulletIndent1\">For <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a>:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Preexisting renal impairment:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Drug is contraindicated </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Renal impairment during therapy: </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>CrCl &lt;10 <span class=\"nowrap\">mL/min</span> &ndash; Avoid or treat with caution at a reduced dose</p><p/><p class=\"bulletIndent1\">For <a href=\"topic.htm?path=lomustine-drug-information\" class=\"drug drug_general\">lomustine</a>:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> &ndash; 25 percent dose reduction</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CrCl &lt;10 <span class=\"nowrap\">mL/min</span> &ndash; 50 percent dose reduction</p><p/><p>In patients with ESRD, there are no guidelines for the dosing of <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a>. For <a href=\"topic.htm?path=lomustine-drug-information\" class=\"drug drug_general\">lomustine</a>, some clinicians recommend a 50 to 75 percent dose reduction in patients undergoing hemodialysis or peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Temozolomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">Temozolomide</a> is an orally active alkylating agent with efficacy in brain tumors. Patients with mild to moderate renal dysfunction have similar pharmacokinetics compared with those who have normal function, although patients with severe renal dysfunction have not been studied [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/39\" class=\"abstract_t\">39</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=604da6f4-e0ef-4c99-8165-18adbcd8ba1f&amp;token=FUjCqo0Di/D8yEwoJIbCMPjU2ld0S4uZ1hTSS1r3GskFXBCkdrQl/D3984Mqe17mWPCwfu3F6cyQWOTLAsPzIZQPj+Uq9fYOXCcOIAGrWfdn9BkytQtDf6MKksV0gNmy&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for temozolomide does not provide guidance for dose reduction in the setting of preexisting renal insufficiency or for patients undergoing dialysis. Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> suggest close monitoring of patients with severe renal impairment, with consideration given to dose modification. </p><p>Experience with <a href=\"topic.htm?path=temozolomide-drug-information\" class=\"drug drug_general\">temozolomide</a> in patients undergoing hemodialysis is very limited [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/40\" class=\"abstract_t\">40</a>]. </p><p class=\"headingAnchor\" id=\"H3085716384\"><span class=\"h2\">Trabectedin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trabectedin-drug-information\" class=\"drug drug_general\">Trabectedin</a> is a marine-derived alkylating agent that is approved for treatment of advanced soft tissue sarcoma. Cases of renal failure (occasionally fatal) have been reported, some of which are attributable to rhabdomyolysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/41-45\" class=\"abstract_t\">41-45</a>].</p><p>According to the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472bd78e-be17-4b9d-90f4-9482c3aec9ff&amp;token=FGDCJ3EnrI50N5eop5oYgYpIAg8Zwvc5FlbuuYfPHo9jz9wr5m4SuEmq4PbX16y0CuMW/lBnJ+e2kRDbuQzN+2CGVAeqf7rUgp1oN46KZkOXPQnyAoZ7AQhamQIW4Lbi&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a>, dose adjustment is not needed for CrCl &ge;30 <span class=\"nowrap\">mL/min;</span> there is no dose adjustment provided for more severe renal insufficiency as dosing has not been specifically studied in this population. Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend that the drug not be used in patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span>. Neither hemodialysis nor peritoneal dialysis enhances elimination of <a href=\"topic.htm?path=trabectedin-drug-information\" class=\"drug drug_general\">trabectedin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/46,47\" class=\"abstract_t\">46,47</a>].</p><p class=\"headingAnchor\" id=\"H4095103962\"><span class=\"h1\">ANTIMETABOLITES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The elimination of many antimetabolites, including <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a>, and <a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">pentostatin</a>, is at least partially dependent upon kidney function. Of the clinically useful antimetabolites, only methotrexate is associated with significant renal toxicity.</p><p class=\"headingAnchor\" id=\"H702282824\"><span class=\"h2\">Capecitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a>, which is cleared through nonrenal mechanisms and therefore does not require dose adjustment in patients with renal dysfunction, systemic exposure to the oral fluoropyrimidine <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> is higher in patients with moderate (creatine clearance [CrCl] 30 to 50 <span class=\"nowrap\">mL/min)</span> and severe (CrCl &lt;30 <span class=\"nowrap\">mL/min)</span> renal impairment. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30830d24-1421-4c25-9b6b-c15705aa4357&amp;token=n+GoQ1EGoZf1XjjmxPjOw+ZDo1Mex6ZTyW1Alqi0KbqwZPhtBSwt/JQEItUlZM7nEvu893sPfOx9OQnneQHeY0oY416xUwBuSvRH23IELKUtm8TOBVRok2rFv27MSTCB&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for capecitabine suggests a 25 percent dose reduction in patients with CrCl 30 to 50 <span class=\"nowrap\">mL/min</span> and that the drug is contraindicated in those with more severe renal impairment. The same recommendation is made in guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>.</p><p>However, these recommendations were based upon a single phase II trial that included a total of four patients with severe renal impairment (glomerular filtration rate [GFR] &lt;30 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/48\" class=\"abstract_t\">48</a>]; among these patients, there was a high rate of grade 3 or 4 adverse events, which led to a shorter than expected duration of treatment. Some suggest that with close monitoring and dose modification based upon the incidence and severity of adverse events,&nbsp;<a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a>&nbsp;can be safely administered to patients with severe renal impairment, including those on hemodialysis, if there is no safe alternative to its use. One study retrospectively evaluated the use of capecitabine in 12 patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> or end-stage renal disease (ESRD) on dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/49\" class=\"abstract_t\">49</a>]; with reductions of up to 50 percent of the starting dose in patients who developed adverse effects, the drug was well tolerated. For patients undergoing dialysis, the drug should be given afterward.</p><p class=\"headingAnchor\" id=\"H3789765438\"><span class=\"h2\">Clofarabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">Clofarabine</a> is a purine nucleoside analog that exerts its antineoplastic effect by inhibiting DNA synthesis and the enzyme ribonucleotide reductase. It is approved for acute lymphoblastic leukemia in children, and it is also being used for relapsed or refractory acute myeloid leukemia and acute lymphoblastic leukemia in adults. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia-in-adults#H11\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory acute lymphoblastic leukemia in adults&quot;, section on 'Clofarabine'</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-myeloid-leukemia#H8\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory acute myeloid leukemia&quot;, section on 'Remission re-induction'</a>.)</p><p>Two case reports describe severe renal injury shortly after drug administration; one patient was found to have 4 g of proteinuria, and the other developed anuria and required dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/50,51\" class=\"abstract_t\">50,51</a>]. No biopsy data exist to help propose a mechanism of injury in these patients, but ribonucleoside reductase may be contributing to podocyte injury and the development of proteinuria [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/50\" class=\"abstract_t\">50</a>].</p><p>The magnitude of nephrotoxicity risk is unclear. In one study, the risk of acute kidney injury (AKI) was as high as 55 percent following use of <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a> in patients undergoing hematopoietic cell transplantation [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/52\" class=\"abstract_t\">52</a>]. Age was the strongest predictor of AKI. The area under the curve of concentration X time (AUC, <span class=\"nowrap\">mg/mL</span> x min) was higher in patients who developed AKI; those with the highest dose-normalized AUCs experienced the most severe grades of AKI. One of those patients had a kidney biopsy that showed acute toxic tubular necrosis as the likely mechanism of injury. </p><p>Renal insufficiency increases drug exposure, which might worsen treatment-related toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/53,54\" class=\"abstract_t\">53,54</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe6ff0f9-7610-4a69-9b75-da7ec4bb7744&amp;token=d4zUovyHURpQOM0Hqhr9KvNnspXHC5x/7rdLGVp/0Cy2KFw/kQqtjrgFJgS7Vg8lAto5n5CfhgNEKfDNLx/TV2Ch+LZAU4CJGuwEMwNb4RnKJFnZQVMxEAoKjKRBAKtG&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a> suggests a 50 percent dose reduction for patients with a baseline CrCl of 30 to 60 <span class=\"nowrap\">mL/min</span>. There is insufficient information for dose recommendations in patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> or on hemodialysis. Clofarabine has not been well studied in patients undergoing dialysis; there is one case report suggesting that the drug is not dialyzable [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/55\" class=\"abstract_t\">55</a>]. </p><p>For patients who develop grade 3 or higher increases in creatinine during treatment (<a href=\"image.htm?imageKey=HEME%2F91253\" class=\"graphic graphic_table graphicRef91253 \">table 2</a>), the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe6ff0f9-7610-4a69-9b75-da7ec4bb7744&amp;token=d4zUovyHURpQOM0Hqhr9KvNnspXHC5x/7rdLGVp/0Cy2KFw/kQqtjrgFJgS7Vg8lAto5n5CfhgNEKfDNLx/TV2Ch+LZAU4CJGuwEMwNb4RnKJFnZQVMxEAoKjKRBAKtG&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends discontinuing the drug and reinitiating it with a 25 percent dose reduction after renal function has stabilized. Guidelines are not available from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>. </p><p class=\"headingAnchor\" id=\"H1991902678\"><span class=\"h2\">Cytarabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">Cytarabine</a> is used for the treatment of acute leukemia and intrathecally for treatment and prophylaxis of meningeal leukemia. The drug is predominantly excreted in the urine as an inactive metabolite. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b48842dd-c5c9-484c-a3f5-cb883919b418&amp;token=2Gkfgd9zM8urQEtmWrFucpDHag60YGbmOt39wtbuKpsspMsjpNaR7zU+YWPnj2CC5Tcp1MRfbKdeU2PzPgZPaRt/A2CT2PqUSEKnGX5BDRRvWzS7rH/qcHLHBdtJhhC0&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for cytarabine does not contain renal dose adjustment guidelines. However, guidelines are available from others suggesting dose reduction in the setting of renal impairment for patients receiving high-dose cytarabine (eg, from 3 to 2 <span class=\"nowrap\">g/m<sup>2</sup></span> or schedule modification from every 12 to every 24 hours) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16,56\" class=\"abstract_t\">16,56</a>]. Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> suggest the need for dose reduction if CrCl is &lt;60 <span class=\"nowrap\">mL/min</span>. Cytarabine has not been well studied in patients undergoing dialysis.</p><p class=\"headingAnchor\" id=\"H178323790\"><span class=\"h2\">Fludarabine and cladribine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">Fludarabine</a> and <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a> have not been associated with renal dysfunction except in the context of tumor lysis syndrome. (See <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors#H10\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;, section on 'Hematologic malignancies'</a>.)</p><p>Approximately one-half of each administered dose of <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> is excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/57\" class=\"abstract_t\">57</a>]. Specific dose adjustment guidelines are available from a number of groups, all of which differ substantially:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc&amp;token=tWmVGj2s0+9J4Z5DcjClZqXb2VEAoUqX1Pf17MVuZ5NXRjxjnhOdTwUlzOSXXWWwTxhH54ePu2nNqD8THD7oOSPJODT5Hdj9iN7w0sloqo7oV+08QPI+XmYoTIarc+/P&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> recommends a 20 percent dose reduction for CrCl 30 to 70 <span class=\"nowrap\">mL/min</span> and that the drug not be administered for more severe renal insufficiency.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommends a 50 percent dose reduction for CrCl 30 to 70 <span class=\"nowrap\">mL/min</span> and that the drug not be used for CrCl &lt;30 <span class=\"nowrap\">mL/min</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff suggests a 25 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Others suggest a 20 percent dose reduction for CrCl 50 to 79 <span class=\"nowrap\">mL/min,</span> a 40 percent dose reduction for CrCl 30 to 49 <span class=\"nowrap\">mL/min,</span> and that the drug be avoided for CrCl &lt;30 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p>Twenty to 35 percent of each dose of <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a> is excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/58\" class=\"abstract_t\">58</a>], but there are no available data upon which to base a recommendation for dose modification in patients with renal insufficiency. Recommendations from expert groups are variable:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines are not provided in the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&amp;token=lUxhKMi/zzvYYfP09Q9MlBF7btlLD4LNBvKuBAl8/ahwoCHfs1LnQ89UEl/eq7uZw9yuc/VXdMzlw3Ei7D/Yl1QD/KjeJH8twh6pMshC9fcmwRo838+M85a0SpXngWII&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff recommends a 25 percent dose reduction for patients with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommends a 25 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent reduction for CrCl &le;10 <span class=\"nowrap\">mL/min</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Others suggest a 30 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p>There are no recommendations for either drug in patients undergoing hemodialysis. In patients undergoing peritoneal dialysis, some clinicians recommend a 50 percent dose reduction for <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> and <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,22\" class=\"abstract_t\">8,22</a>].</p><p class=\"headingAnchor\" id=\"H3822453368\"><span class=\"h2\">Gemcitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">Gemcitabine</a> is a cell cycle-specific pyrimidine antagonist; the most common form of renal toxicity is AKI with microangiopathic hemolytic anemia (thrombotic microangiopathy [TMA], previously referred to as thrombotic thrombocytopenic <span class=\"nowrap\">purpura/hemolytic</span> uremic syndrome [TTP-HUS]) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/59-61\" class=\"abstract_t\">59-61</a>]. The incidence ranges from 0.015 to 1.4 percent, and in some reports (but not others [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/62\" class=\"abstract_t\">62</a>]), risk is highest in those who have received cumulative gemcitabine doses over 20,000 <span class=\"nowrap\">mg/m<sup>2</span> </sup>[<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/61\" class=\"abstract_t\">61</a>]. Prior therapy with <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> C may be a risk factor for the development of TMA [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/60\" class=\"abstract_t\">60</a>]. </p><p>This diagnosis should be considered in a patient who develops Coombs-negative hemolytic anemia, thrombocytopenia, AKI, <span class=\"nowrap\">and/or</span> neurologic findings while receiving <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>. Drug discontinuation is recommended if this occurs. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H174813\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Cancer therapies'</a>.) </p><p>Although patients with elevated creatinine levels may have greater than expected toxicity from <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>, even at reduced doses [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/63\" class=\"abstract_t\">63</a>], a dose modification scheme based upon preexisting renal dysfunction has not been developed. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1170be9-f12d-475e-bad6-544005f12303&amp;token=/4988aBCQvx4qq+7UnjTvvZwaaTEOxfIf/2SACybuuIOJjRqdmn0Z6htd/nSg4whgMDK1qcRsmYXfjy7VphIbY669Sbuqxvs3Ts0gd/wXzKaDYrIVNFPEjnqEKWWKzTt&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for gemcitabine does not provide guidance for dose reduction in the setting of preexisting significant renal dysfunction. <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines state only that gemcitabine should be used with caution in patients with renal insufficiency.</p><p>Retrospective reports suggest that administration of <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> is feasible in patients with ESRD on hemodialysis. While gemcitabine removal by hemodialysis has never been studied, its inactive metabolite difluorodeoxycytidine is removed by hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/64\" class=\"abstract_t\">64</a>]. Guidelines suggest that hemodialysis be initiated 6 to 24 hours after each dose of gemcitabine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10,65\" class=\"abstract_t\">10,65</a>]. Patients receiving long-term hemodialysis may be at a higher risk of developing significant gemcitabine-related hematological toxicity. There are no available data or dosing guidelines for patients undergoing peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H935841151\"><span class=\"h2\">Hydroxyurea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">Hydroxyurea</a> is used for treatment of non-chronic myelogenous leukemia (CML) myeloproliferative disorders and in patients with sickle cell anemia to reduce the frequency of painful crises and the need for blood transfusions. (See <a href=\"topic.htm?path=hydroxyurea-use-in-sickle-cell-disease\" class=\"medical medical_review\">&quot;Hydroxyurea use in sickle cell disease&quot;</a> and <a href=\"topic.htm?path=prognosis-and-treatment-of-polycythemia-vera#H697280338\" class=\"medical medical_review\">&quot;Prognosis and treatment of polycythemia vera&quot;, section on 'Hydroxyurea'</a> and <a href=\"topic.htm?path=management-of-primary-myelofibrosis#H1097017349\" class=\"medical medical_review\">&quot;Management of primary myelofibrosis&quot;, section on 'Hydroxyurea'</a> and <a href=\"topic.htm?path=prognosis-and-treatment-of-essential-thrombocythemia#H10\" class=\"medical medical_review\">&quot;Prognosis and treatment of essential thrombocythemia&quot;, section on 'Hydroxyurea'</a>.)</p><p>Approximately 40 to 50 percent of the drug is excreted renally [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/66,67\" class=\"abstract_t\">66,67</a>], and dose reductions are needed in patients with renal dysfunction. Recommendations from expert groups are variable:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1bdd4b-043a-4cf6-b1ff-8de49e02b7a6&amp;token=ia2uXSApvgQ8IxQyI5Mdc6PztYulgF6hWdxtwHLusmXiDj3o4uPBPcJhz1zeGwvwRQ3e3rgEnoRs0eGrw5oUAkhuWO0qEi3fZAMkwNDxZ99HD9+5YWMqvkUMY3SDGx/U&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a> suggests a 50 percent dose reduction for individuals with CrCl &lt;60 <span class=\"nowrap\">mL/min</span> or for those with ESRD who are undergoing hemodialysis, regardless of the intent of therapy. On dialysis days, administer hydroxyurea after dialysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines for use of <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a> in malignant disease suggest a 50 percent reduction in the initial dose for patients with CrCl 10 to 60 <span class=\"nowrap\">mL/min</span> and that the drug be discontinued for CrCl &lt;10 <span class=\"nowrap\">mL/min</span>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Others suggest an alternative dose reduction schema for patients with malignant disease, with a 50 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and an 80 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> or those with ESRD who are on hemodialysis (with administration after dialysis) or peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,22\" class=\"abstract_t\">8,22</a>]. </p><p/><p>For patients receiving <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a>, serum creatinine should be periodically reassessed during treatment. A point-of-care device for measuring serum creatinine (the i-STAT system) that is used for routine testing in some clinical laboratories can give a falsely elevated creatinine measurement [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/6\" class=\"abstract_t\">6</a>]. Thus, individuals treated with hydroxyurea who have high serum creatinine should be retested using a different method to distinguish this artifact from true renal disease. (See <a href=\"topic.htm?path=hydroxyurea-use-in-sickle-cell-disease#H3620003872\" class=\"medical medical_review\">&quot;Hydroxyurea use in sickle cell disease&quot;, section on 'Falsely elevated serum creatinine and other laboratory tests'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Methotrexate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> at doses less than 0.5 to 1.0 <span class=\"nowrap\">g/m<sup>2</sup></span> is usually not associated with renal toxicity unless underlying renal dysfunction is present. In contrast, high-dose intravenous methotrexate (1 to 15 <span class=\"nowrap\">g/m<sup>2</sup>)</span> can precipitate in the tubules and induce tubular injury; at particular risk are patients who are volume depleted and those who excrete acidic urine. Maintenance of adequate urinary output and alkalinization will lessen the probability of methotrexate precipitation. This topic is discussed in detail elsewhere. (See <a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate#H13\" class=\"medical medical_review\">&quot;Therapeutic use and toxicity of high-dose methotrexate&quot;, section on 'Renal toxicity'</a> and <a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure#H4164341\" class=\"medical medical_review\">&quot;Crystal-induced acute kidney injury (acute renal failure)&quot;, section on 'Methotrexate'</a>.)</p><p><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> can also produce a transient decrease in GFR, with complete recovery within six to eight hours of discontinuing the drug. The mechanism responsible for this functional renal impairment involves afferent arteriolar constriction or mesangial cell constriction that produces reduced glomerular capillary surface area and diminished glomerular capillary perfusion and pressure [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/68\" class=\"abstract_t\">68</a>]. Methotrexate has also been associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> excretion is decreased in patients who have renal insufficiency, and higher levels of bone marrow and gastrointestinal toxicity may result [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/69\" class=\"abstract_t\">69</a>]. Patients with ileal conduits and those with third-space fluid collections (eg, ascites, pleural effusion) may also experience greater methotrexate toxicity, particularly if their CrCl is low [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/70\" class=\"abstract_t\">70</a>]. For patients with an ileal conduit, the mechanism is thought to be increased reabsorption of excreted drug through the mucosa of the conduit [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/71,72\" class=\"abstract_t\">71,72</a>].</p><p>Guidelines from expert groups for dose modification of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> in the setting of renal insufficiency differ: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&amp;token=2P2VHDFZjII9/IBIax6sp7Fuw0kvfpiwXTIkw1TM1iVnDTxv2wonxoOcom9mqHJhR7Nx63UW+imvNWwf4NoNW6hmpHwMnzq+NE60OtXM/cGGizztPPPngjYknXq9k3BV&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> does not contain recommended dose adjustments for renal insufficiency, stating only that serum creatinine must be normal and CrCl must be &gt;60 <span class=\"nowrap\">mL/min</span> prior to initiation of treatment. However, dose modification guidelines have been proposed by several clinical groups [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,16\" class=\"abstract_t\">8,16</a>]. As examples: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For adults, Aronoff recommends a 50 percent dose decrease in patients with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and that the drug be avoided in patients with worse kidney function [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines suggest a 25 percent dose reduction for CrCl 80 <span class=\"nowrap\">mL/min,</span> a 40 percent dose reduction for CrCl 60 <span class=\"nowrap\">mL/min,</span> a 50 percent dose reduction for CrCl 50 <span class=\"nowrap\">mL/min,</span> and that the drug be discontinued for CrCl &lt;50 <span class=\"nowrap\">mL/min</span>. They also state that less conservative dose modification could be considered for low-dose regimens (&lt;50 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> and that high-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> should only be administered if the CrCl is &gt;60 <span class=\"nowrap\">mL/min</span>.</p><p/><p>Drug removal by hemodialysis is incomplete since <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> is protein bound and therefore not readily dialyzable [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/73-75\" class=\"abstract_t\">73-75</a>]. However, methotrexate can be removed by hemodialysis, especially when using high-flux hemodialysis membranes. (See <a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure#H4164341\" class=\"medical medical_review\">&quot;Crystal-induced acute kidney injury (acute renal failure)&quot;, section on 'Methotrexate'</a>.)</p><p>For patients who are receiving low-dose oral <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> and are undergoing hemodialysis or peritoneal dialysis, some suggest a 50 to 75 percent dose reduction [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,10,22\" class=\"abstract_t\">8,10,22</a>] and that the drug be administered after dialysis. Most guidelines suggest avoidance of high-dose methotrexate in the setting of ESRD.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Pemetrexed</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">Pemetrexed</a> is a derivative of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> that is approved for treatment of advanced non-small cell lung cancer and pleural mesothelioma. (See <a href=\"topic.htm?path=systemic-treatment-for-unresectable-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Systemic treatment for unresectable malignant pleural mesothelioma&quot;</a> and <a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation#H6\" class=\"medical medical_review\">&quot;Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation&quot;, section on 'Initial cytotoxic regimen'</a>.)</p><p><a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">Pemetrexed</a> has been associated with renal damage (including acute tubular necrosis, interstitial edema, renal tubular acidosis, and diabetes insipidus) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/76-78\" class=\"abstract_t\">76-78</a>]. The risk of AKI is thought to be low (1 to 5 percent in some clinical studies according to the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5a860f3-37ec-429c-ae04-9c88d7c55c08&amp;token=gu7OywewzZmBvGJGMWEaqLly4P6rEwKC0JozbfMDyw+cR00fYRd9Fj303JFvcKJhZD4d524OCI2hGPzGL8nnSSc9bghICCMrhPSzAu39sAMS2CD0qmRM09JdbacAbee8&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a>), but higher risks have been reported by others (21 to 54 percent), mainly in patients with non-small cell lung cancer treated with combination chemotherapy that includes pemetrexed [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/78,79\" class=\"abstract_t\">78,79</a>]. Baseline renal impairment appears to be a risk factor for AKI [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/78,79\" class=\"abstract_t\">78,79</a>]. Some cases may not be reversible [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/78,79\" class=\"abstract_t\">78,79</a>].</p><p><a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">Pemetrexed</a> is primarily excreted unchanged by renal excretion. Dose adjustment is not necessary in patients with CrCl &ge;45 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/80\" class=\"abstract_t\">80</a>]; however, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5a860f3-37ec-429c-ae04-9c88d7c55c08&amp;token=gu7OywewzZmBvGJGMWEaqLly4P6rEwKC0JozbfMDyw+cR00fYRd9Fj303JFvcKJhZD4d524OCI2hGPzGL8nnSSc9bghICCMrhPSzAu39sAMS2CD0qmRM09JdbacAbee8&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for pemetrexed recommends that the drug not be used in patients with CrCl &lt;45 <span class=\"nowrap\">mL/min</span>. Furthermore, there are recommendations for avoidance of nonsteroidal antiinflammatory drugs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79 <span class=\"nowrap\">mL/min)</span> because of the potential for decreased clearance of pemetrexed. Similar guidelines are available from others [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>], including <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>.</p><p>There are no data on the use of <a href=\"topic.htm?path=pemetrexed-drug-information\" class=\"drug drug_general\">pemetrexed</a> in patients undergoing hemodialysis or peritoneal dialysis, and specific recommendations are not available from any group.</p><p class=\"headingAnchor\" id=\"H3902156842\"><span class=\"h2\">Pentostatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">Pentostatin</a> is used for treatment of hairy cell and other leukemias, and for treatment of acute graft-versus-host disease. (See <a href=\"topic.htm?path=treatment-of-hairy-cell-leukemia#H6\" class=\"medical medical_review\">&quot;Treatment of hairy cell leukemia&quot;, section on 'Pentostatin'</a> and <a href=\"topic.htm?path=treatment-of-t-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">&quot;Treatment of T cell prolymphocytic leukemia&quot;</a> and <a href=\"topic.htm?path=treatment-of-acute-graft-versus-host-disease#H11944410\" class=\"medical medical_review\">&quot;Treatment of acute graft-versus-host disease&quot;, section on 'Pentostatin'</a>.)</p><p>Approximately 90 percent of each dose is excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/81\" class=\"abstract_t\">81</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3&amp;token=5NM8DW0/wrn32n+Hihu8M4ipf3DfJZSm+HS4y5KV40DkkbvpfGM0IeohK35BdQL1WOP35iF6VKEW8GbeDF1OBb+k8hd+N0Xa1vc+ohloleguMiKWefLIIHr9KNQm67jI&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">pentostatin</a> does not contain dose adjustment guidelines for patients with renal insufficiency, stating only that there are insufficient data to recommend a starting or subsequent dose for patients with CrCl &lt;60 <span class=\"nowrap\">mL/min</span>. However, others suggest a 50 percent dose reduction for patients with CrCl &lt;60 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16,22,82,83\" class=\"abstract_t\">16,22,82,83</a>].</p><p class=\"headingAnchor\" id=\"H203227473\"><span class=\"h2\">Pralatrexate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pralatrexate-drug-information\" class=\"drug drug_general\">Pralatrexate</a> is an antifolate used for the treatment of relapsed or refractory peripheral T cell lymphoma. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma#H6\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory peripheral T cell lymphoma&quot;, section on 'Pralatrexate'</a>.)</p><p><a href=\"topic.htm?path=pralatrexate-drug-information\" class=\"drug drug_general\">Pralatrexate</a> is partially excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/84\" class=\"abstract_t\">84</a>]. The available evidence suggests that drug exposure in patients with mild to moderate renal impairment is similar to that in patients with normal renal function [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/85\" class=\"abstract_t\">85</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e4cf15b-bf7b-4b83-863e-e9ef27741a51&amp;token=FfRYpix97fcT2Fu0oaVy9movH5uvOIFy7xx1o8IAcsgXcXw9oTcw0rLYxwJ/uy2bzsyns/vrsl+YPCgh5vMSj8Aam1R8Ri4CGNKzXt51Xpk0knsktIzKQHksj88YLZSl&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> suggests a reduced dose for patients with severe renal impairment (CrCl &lt;30 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>). There are no data on the use of pralatrexate in patients undergoing hemodialysis or peritoneal dialysis, and specific recommendations are not available from any group.</p><p class=\"headingAnchor\" id=\"H1949885050\"><span class=\"h1\">ANTIMICROTUBULE AGENTS</span></p><p class=\"headingAnchor\" id=\"H3285757041\"><span class=\"h2\">Taxanes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The taxanes <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> undergo minimal renal excretion. The limited data indicate that both can be safely administered to patients with renal insufficiency and that dose modification is not required [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. Both paclitaxel [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/86-89\" class=\"abstract_t\">86-89</a>] and docetaxel [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/90\" class=\"abstract_t\">90</a>] have been administered safely at standard doses to patients on chronic peritoneal or hemodialysis, although some guidelines suggest a dose reduction for docetaxel in patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>].</p><p><a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">Cabazitaxel</a> is a new semisynthetic taxane. Cases of renal failure were reported in a randomized trial conducted in men with metastatic prostate cancer, including four with a fatal outcome. Most occurred in association with sepsis, dehydration, or obstructive uropathy. Hemorrhagic cystitis has also been reported. (See <a href=\"topic.htm?path=chemotherapy-in-castration-resistant-prostate-cancer#H12\" class=\"medical medical_review\">&quot;Chemotherapy in castration-resistant prostate cancer&quot;, section on 'Prior docetaxel'</a> and <a href=\"topic.htm?path=cystitis-in-patients-with-cancer#H10\" class=\"medical medical_review\">&quot;Cystitis in patients with cancer&quot;, section on 'Chemotherapy-induced cystitis'</a>.)</p><p>There are no guidelines for <a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">cabazitaxel</a> dose reduction in patients with mild to moderate renal insufficiency. In population-based pharmacokinetic trials, there was no difference in clearance in patients with mild or moderate renal insufficiency (creatine clearance [CrCl] &lt;80 but &gt;30 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/91\" class=\"abstract_t\">91</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa&amp;token=Li/bil6wzP5mK16t7HqJYtmJNWvHgMXMPK581qSrHZEb6tWlHL4hH//4Y3VyGbhakMDNPm3H2xDRrI46YfZ3u8DtH16pch3zRkIbgYibQP7HhgFtJi/j4oVBlC8FgI2y&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> recommends no dose adjustment for patients not requiring hemodialysis, and careful monitoring during treatment in patients with end-stage renal disease (ESRD; CrCl &lt;15 <span class=\"nowrap\">mL/min/1</span>.73m<sup>2</sup>). Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> suggest discontinuation of therapy for CrCl &lt;15 <span class=\"nowrap\">mL/min</span>. </p><p class=\"headingAnchor\" id=\"H531929894\"><span class=\"h2\">Vinca alkaloids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">Vincristine</a>, <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">vinblastine</a>, and <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">vinorelbine</a> have all been associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a small number of treated patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/92,93\" class=\"abstract_t\">92,93</a>]. (See <a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">&quot;Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)&quot;</a>.)</p><p>All three drugs are mainly eliminated through hepatic metabolism, with a minority of the dose (8 to 20 percent) recovered in the urine. Both the United States prescribing information and guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> indicate that dose reduction is not needed for patients with renal insufficiency who are not undergoing dialysis. However, a lower starting dose of <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">vinorelbine</a> has been suggested by some authors in patients with ESRD who are undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H1117729775\"><span class=\"h2\">Eribulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=eribulin-drug-information\" class=\"drug drug_general\">Eribulin</a> mesylate, a synthetic analogue of halichondrin B (a substance derived from a marine sponge), inhibits the polymerization of tubulin and microtubules. It is used for the treatment of advanced breast cancer and soft tissue sarcoma. (See <a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy#H2993609\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic breast cancer in women: Chemotherapy&quot;, section on 'Eribulin'</a> and <a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma#H2445403424\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic soft tissue sarcoma&quot;, section on 'Eribulin'</a>.) </p><p>Less than 10 percent of the drug is excreted in the urine. Formal pharmacokinetic trials have not been conducted in patients with renal impairment. The only available data suggest that patients with moderate or severe renal impairment can tolerate doses of 1.4 <span class=\"nowrap\">mg/m<sup>2</sup></span> without unexpected toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/94\" class=\"abstract_t\">94</a>]. However, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822&amp;token=6b/fGE6bulbmWOvpvUB1lFEQHHoSlFn8EyK0LyI0DhZuyVXeuCManFAubKbX53mSCgPSq6NVzEqFoDCLu017IbaY496m/SxHYVMKtGlLRG7aCO48pPW0F+dxySS1Ak7i&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=eribulin-drug-information\" class=\"drug drug_general\">eribulin</a> recommends a lower starting dose in patients with moderate or severe renal insufficiency (CrCl 15 to 49 <span class=\"nowrap\">mL/min)</span>. <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines recommend a lower starting dose in patients with CrCl 15 to 50 <span class=\"nowrap\">mL/min</span> and that the drug be avoided in patients with ESRD (CrCl &lt;15 <span class=\"nowrap\">mL/min)</span>. Others suggest that the drug be avoided in individuals with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>]. </p><p class=\"headingAnchor\" id=\"H3369160442\"><span class=\"h1\">ANTITUMOR ANTIBIOTICS</span></p><p class=\"headingAnchor\" id=\"H1057052687\"><span class=\"h2\">Anthracyclines and related agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anthracyclines such as <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> and <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> have been known to cause nephrotic syndrome with renal lesions consistent with minimal change disease, focal segmental glomerular sclerosis not otherwise specified (NOS), or collapsing glomerulopathy [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/95\" class=\"abstract_t\">95</a>]. In addition, <a href=\"topic.htm?path=pegylated-liposomal-doxorubicin-drug-information\" class=\"drug drug_general\">pegylated liposomal doxorubicin</a> has been associated with renal thrombotic microangiopathy, nephrotic syndrome, and acute kidney injury [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/96-98\" class=\"abstract_t\">96-98</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H174813\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Cancer therapies'</a>.)</p><p><a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">Doxorubicin</a>, <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a>, <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">mitoxantrone</a>, and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a>, as well as their major metabolites, are excreted mainly through the bile and, to a lesser extent, by urinary excretion. Although Aronoff recommends no dose reduction for epirubicin or any other anthracycline in patients with renal failure [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>], others disagree:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The United States prescribing information recommends that lower doses of <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7ec5ec1-fb05-4c78-b821-9aea638cf144&amp;token=MOEjGLT4YLewkfvr9wKUqpt5+Cbesp+bxLQY5QJCakESvTBaMFMZzWNdMkZwSectuKgYS1KCxpT4bIYjFIDCfKOek0kIHFnTWSRmPxq0p/yY5F2x6aXdmOEcWbhD3aBk&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">epirubicin</a> be considered in patients with severe renal impairment (serum creatinine &gt;5 <span class=\"nowrap\">mg/dL)</span>. A 50 percent dose reduction is also recommended for <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf9bf9c-017a-4e28-9a53-23fecda0d39e&amp;token=6E/3kExRy+/1H4HOG1jE+83v/x9VE0KY2bQHoh5m+Up+Qb1dvDrbs2NPGmfStCwUb8v/WxcdHCpUKsZvGCyRTYHOdskssgHe9GmhksMGuxLgPMP+GNPbN1mdYpQe87i4&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">daunorubicin</a> in patients with serum creatinine &gt;3 <span class=\"nowrap\">mg/dL</span>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Guidelines from <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend a 50 percent dose reduction for both <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> if the creatine is greater than two times the upper limit of normal (ULN).</p><p/><p>Although experience is limited, some suggest that dose adjustment is not needed for <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a> or <a href=\"topic.htm?path=epirubicin-drug-information\" class=\"drug drug_general\">epirubicin</a> in patients undergoing hemodialysis or peritoneal dialysis, and that administration should follow hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,10\" class=\"abstract_t\">8,10</a>].</p><p class=\"headingAnchor\" id=\"H1161271807\"><span class=\"h2\">Bleomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Renal toxicity is not described as a complication of <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a> therapy. However, renal insufficiency is known to alter bleomycin elimination, particularly in patients with creatine clearance [CrCl] &lt;25 to 35 <span class=\"nowrap\">mL/min,</span> increasing the likelihood of treatment-related toxicity, particularly pulmonary toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/99-101\" class=\"abstract_t\">99-101</a>]. (See <a href=\"topic.htm?path=bleomycin-induced-lung-injury#H7\" class=\"medical medical_review\">&quot;Bleomycin-induced lung injury&quot;, section on 'Dose and renal insufficiency'</a>.) </p><p>Few patients with renal impairment receiving <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a> have been studied [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/19,102\" class=\"abstract_t\">19,102</a>]; however, dose reduction guidelines are available from several groups:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428&amp;token=WSU8Hqu18XVTm/6JtWSclZPIxEBPhNyb7oBjMFrJPot4bNrA0myYh8M4LnvMhNlRCncOv+6etdSBFQpWSG4Vqn1EjWyK06FZCDGYU47P0dPeFkiHCTibUHkrCLOQ7Hbx&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> specifies a dose reduction schema for patients with CrCl &lt;50 <span class=\"nowrap\">mL/min</span>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff suggests a 25 percent dose reduction for patients with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. These guidelines are endorsed by <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>. </p><p/><p>Specific guidelines are not available for patients undergoing hemodialysis or peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H1646397459\"><span class=\"h2\">Mitomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a possible association of <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> with drug-induced thrombotic microangiopathy that has not been definitively established. This subject is discussed in detail elsewhere. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H174813\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Cancer therapies'</a>.)</p><p>Less than 20 percent of <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> is excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"abstract_t\">16</a>]. Mitomycin can be administered to patients with renal insufficiency, with close monitoring for signs and symptoms of acute kidney injury. Guidelines differ for dose reduction in the setting of preexisting renal impairment:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d80c6dc0-5f26-4d7a-a0f7-7698ab4f249a&amp;token=98joH0v9XTDayY6Hy3hB+lNAPOKzvwB6WerCiJ8PVH17wcd2G4K3EgMWspJONBPUp5LuMwhZWSCNvD3gyRjsG/4ZP2+JZvJi1aGVN5ZxhCs1nB2Sr3JXpv1sO5KW4QE9&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> states to avoid use in patients with serum creatine &gt;1.7 <span class=\"nowrap\">mg/dL,</span> but it offers no other dose adjustment guidelines. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff recommends a dose reduction of 25 percent only for patients with CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommends that the drug be withheld for serum creatinine &gt;150 <span class=\"nowrap\">micromol/L</span> (1.7 <span class=\"nowrap\">mg/dL)</span> or in patients with moderate to severe renal impairment.</p><p/><p>There are no specific dosing guidelines in patients undergoing hemodialysis. Some clinicians recommend a 25 percent dose reduction in patients undergoing peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H4029653556\"><span class=\"h1\">PLATINUM AGENTS</span></p><p class=\"headingAnchor\" id=\"H3902995358\"><span class=\"h2\">Cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is one of the most commonly used antineoplastic drugs, and it is also one of the most nephrotoxic. Cisplatin is associated with acute kidney injury (AKI), thrombotic microangiopathy (TMA), hypomagnesemia, proximal tubular dysfunction (ie, Fanconi-like syndrome), and anemia that is out of proportion to the drug's myelosuppressive effects. Hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/103\" class=\"abstract_t\">103</a>]. Cisplatin-induced renal insufficiency is discussed in detail elsewhere. (See <a href=\"topic.htm?path=cisplatin-nephrotoxicity\" class=\"medical medical_review\">&quot;Cisplatin nephrotoxicity&quot;</a>.)</p><p>The optimal approach to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> therapy in patients with preexisting renal impairment or persistent renal impairment during therapy is unknown. Clinical trial protocols often require a serum creatinine of less than 2.0 <span class=\"nowrap\">mg/dL</span> (177 <span class=\"nowrap\">micromol/L)</span> or a creatinine clearance (CrCl) of &ge;60 <span class=\"nowrap\">mL/min</span> for administration of the full dose of cisplatin, and they exclude patients with more significant renal impairment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/104\" class=\"abstract_t\">104</a>]. This restriction is probably related more to concerns regarding increased nonrenal toxicity (ototoxicity, neuropathy) than to an increased risk of AKI.</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b029f5-0d7e-4e7f-accc-b722aec34c68&amp;token=KzDjmR7NYLJqvamNUXzjhWl3dlBmGPpuQ0lFUEst4rRsVW5QKo6boSy3fS+dMl8cxwDJYNijli7A2g0nE4356PIFDxpyk6CapmWJRsW7sEWdi97rGKyY1ehinf+sVOyH&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> recommends that repeat courses of cisplatin not be given unless or until serum creatinine is &lt;1.5 <span class=\"nowrap\">mg/dL</span> <span class=\"nowrap\">and/or</span> blood urea nitrogen (BUN) is &lt;25 <span class=\"nowrap\">mg/dL;</span> there are no suggested renal dose adjustment guidelines. </p><p>Empiric guidelines have suggested that <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> can be administered at a reduced dose to patients with renal impairment, although extensive data supporting such recommendations are lacking and specific recommendations differ [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,16\" class=\"abstract_t\">8,16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kintzel suggests a 25 percent dose reduction for CrCl 46 to 60 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction for CrCl 30 to 45 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"abstract_t\">16</a>]. These guidelines are endorsed by <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aronoff suggests that <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> can be administered to patients with even more severe renal impairment, recommending a 25 percent dose reduction for CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent dose reduction in those with CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p>Although the available data are scant and predominantly comprised of single case reports, cisplatin-containing chemotherapy combinations have been successfully administered to patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10,105-107\" class=\"abstract_t\">10,105-107</a>]. One guideline suggests that such patients have a 50 to 75 percent reduction in dose and that the drug be administered after hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>]. A 50 percent dose reduction is also recommended for patients undergoing peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,22\" class=\"abstract_t\">8,22</a>].</p><p class=\"headingAnchor\" id=\"H4183676142\"><span class=\"h2\">Carboplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In both experimental and clinical studies, <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> is significantly less nephrotoxic than <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/108,109\" class=\"abstract_t\">108,109</a>]. This increase in safety may reflect the enhanced stability of carboplatin, which has carboxylate and cyclobutane moieties in the cis position rather than chloride [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/109\" class=\"abstract_t\">109</a>]. Hypomagnesemia appears to be the most common manifestation of nephrotoxicity, although it occurs less often than with cisplatin [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/110,111\" class=\"abstract_t\">110,111</a>]. (See <a href=\"topic.htm?path=cisplatin-nephrotoxicity\" class=\"medical medical_review\">&quot;Cisplatin nephrotoxicity&quot;</a>.)</p><p>AKI has been reported, particularly in patients previously treated with several courses of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/109\" class=\"abstract_t\">109</a>]. Direct tubular injury leading to acute tubular necrosis is the primary mechanism. A less common renal side effect is renal magnesium wasting [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/112,113\" class=\"abstract_t\">112,113</a>].</p><p class=\"headingAnchor\" id=\"H787081390\"><span class=\"h3\">AUC dose calculation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The importance of renal clearance to the metabolism and excretion of <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> is emphasized by its usual dosing schema, which is based upon an estimate of the glomerular filtration rate (GFR) and the desired level of drug exposure according to the area under the curve of concentration X time (AUC, <span class=\"nowrap\">mg/mL</span> x min), rather than the more common dosing calculation based upon body surface area <span class=\"nowrap\">(mg/m<sup>2</sup>)</span>.</p><p>Using the desired target AUC (which typically varies between 5 and 7 <span class=\"nowrap\">mg/mL</span> x min) and the estimated GFR, the dose of <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> is then calculated using the Calvert formula: total carboplatin dose (mg) = target AUC x (estimated CrCl + 25). Because of potential changes in weight or renal function, this calculation should be repeated prior to each administered course of carboplatin.</p><p>The following issues are relevant to the <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dose calculation:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Total <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dose is calculated in mg, <strong>not</strong> <span class=\"nowrap\">mg/m<sup>2</sup></span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maximum GFR</strong> &ndash; When using an estimate instead of a direct measurement of GFR to calculate the <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dose using the Calvert formula, calibration of the creatinine assay may impact dosing. In the United States, as of the end of 2010, all laboratories must use a creatinine method that has calibration that is traceable to an Isotope Dilution Mass Spectrometry (IDMS) reference measurement procedure [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/114\" class=\"abstract_t\">114</a>]. However, this gives lower creatinine results than the older measurements, and hence, higher estimates of GFR. This could result in higher calculated carboplatin doses and may potentially result in increased toxicities. The US Food and Drug Administration (FDA) recommends limiting the maximal GFR for the calculation to 125 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/115\" class=\"abstract_t\">115</a>], thereby capping the carboplatin dose for a desired AUC.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Obese patients</strong> &ndash; Another point of unresolved controversy is the appropriate weight to use when calculating estimated GFR. The original Cockcroft-Gault formula to estimate GFR used actual body weight, but none of the patients was obese. Most clinicians use actual body weight in the Cockcroft-Gault formula for nonobese patients, although institutional practice varies. However, the use of actual body weight in the Cockcroft-Gault calculation can result in an overestimate of GFR and a higher than needed <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dose in obese individuals [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/116\" class=\"abstract_t\">116</a>]. The United States Gynecologic Oncology Group (GOG) recommends that actual weight be used for estimation of GFR when using the Cockcroft-Gault equation as long as patients have a body mass index (BMI) of &lt;25 (<a href=\"topic.htm?path=calculator-body-mass-index-bmi-quetelets-index-in-adults\" class=\"calc calc_professional\">calculator 5</a>). For other patients, use of an adjusted weight is suggested (adjusted weight [kg] = [(actual weight - ideal weight) x 0.40] + ideal weight). A calculator for ideal body weight is available (<a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" class=\"calc calc_professional\">calculator 6</a>).</p><p/><p>These issues are all discussed in greater detail elsewhere. (See <a href=\"topic.htm?path=dosing-of-anticancer-agents-in-adults#H390293890\" class=\"medical medical_review\">&quot;Dosing of anticancer agents in adults&quot;, section on 'AUC-based dosing'</a>.)</p><p>Not all carboplatin-containing regimens use AUC-based dosing. For <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dosed on an <span class=\"nowrap\">mg/m<sup>2</sup></span> basis, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4baa639-287b-4d97-923f-ce5c6add531c&amp;token=nuz2kttTcSCNkuI0kVGqAZ+w3Gp/zb1Ky2kistekLOWx4LQZ6SteqXmS7kp04k8KP/D4ewi3vPegtAO6KDiX2Bmz5UO+ww3IM3Bxx6eUweePfw79fsWfuHhojmY3k5bC&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for carboplatin suggests the following dose reduction schema based upon renal function:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 41 to 59 <span class=\"nowrap\">mg/dL</span> &ndash; Reduce initial dose from 300 to 360 <span class=\"nowrap\">mg/m<sup>2</sup></span> to 250 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 16 to 40 <span class=\"nowrap\">mg/dL</span> &ndash; Reduce initial dose to 200 <span class=\"nowrap\">mg/m<sup>2</sup></span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl &le;15 <span class=\"nowrap\">mg/dL</span> &ndash; Not recommended</p><p/><p class=\"headingAnchor\" id=\"H574865793\"><span class=\"h3\">Use in dialysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemotherapy regimens incorporating <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> have been successfully used in patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/117-122\" class=\"abstract_t\">117-122</a>]. Some authors recommend a total dose (in mg) of 25 x AUC and that the dose be administered after hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>]. In patients on peritoneal dialysis, guidelines suggest a 75 percent dose reduction [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,22\" class=\"abstract_t\">8,22</a>].</p><p class=\"headingAnchor\" id=\"H1539158543\"><span class=\"h2\">Oxaliplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a>, clinically significant renal toxicity, such as acute tubular necrosis, is rare, although it does occur with the third-generation platinum compound <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>, sometimes in the setting of immune-mediated intravascular hemolysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/123-126\" class=\"abstract_t\">123-126</a>]. Limited data with oxaliplatin suggest no exacerbation of preexisting mild renal impairment during treatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/127\" class=\"abstract_t\">127</a>]. Oxaliplatin has been associated with TMA in rare single case reports. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H83397\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Oxaliplatin'</a>.) </p><p><a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">Oxaliplatin</a> is predominantly cleared by the kidneys [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/128\" class=\"abstract_t\">128</a>]. Oxaliplatin doses up to 130 <span class=\"nowrap\">mg/m<sup>2</sup></span> every three weeks have been well tolerated in patients with mild to moderate renal dysfunction (CrCl &gt;20 <span class=\"nowrap\">mL/min),</span> and dose reduction appears not to be necessary in these patients [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/129\" class=\"abstract_t\">129</a>]. The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ffb166a-8283-44c0-8590-ecad2743c154&amp;token=M5U+b8QssMbF51C8Q9cS7JLAi7Nyp35/iKM2unfj11Ssyl+QEt1XRGgLOBDgTTaZ96+CahCtYZbCP3XNOCsx8drzvGNHJ0t9JI8qoJ0zC9s5JHHr+y3J6k6Z2tyZYsGC&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for oxaliplatin suggests a reduced starting dose in patients with severe renal impairment (CrCl &lt;30 <span class=\"nowrap\">mL/min),</span> while <a href=\"https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JorOLhpZTAY8/gXkHVhzmfiPOKwEVJ7lkqc5lswInA/+tzETNLud1xtPa27lcp3JA=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines recommend avoiding the drug in such patients.</p><p>Some experts recommend a 30 percent dose reduction in patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>], although others suggest that this is not necessary if hemodialysis is performed shortly after drug administration and the dosing interval is extended to three weeks [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/130\" class=\"abstract_t\">130</a>]. There are no specific guidelines for dose modification in patients undergoing peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H3920114876\"><span class=\"h1\">MISCELLANEOUS CYTOTOXIC AGENTS</span></p><p class=\"headingAnchor\" id=\"H4016699895\"><span class=\"h2\">Arsenic trioxide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">Arsenic trioxide</a> is used for treatment of acute promyelocytic leukemia. (See <a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults#H9\" class=\"medical medical_review\">&quot;Initial treatment of acute promyelocytic leukemia in adults&quot;, section on 'ATO plus ATRA'</a>.)</p><p>While toxic exposure to arsenic can lead to tubulointerstitial disease of the kidney and rhabdomyolysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/131\" class=\"abstract_t\">131</a>], these are only rarely associated with the lower doses of <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">arsenic trioxide</a> used for cancer treatment [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/132\" class=\"abstract_t\">132</a>]. (See <a href=\"topic.htm?path=arsenic-exposure-and-poisoning\" class=\"medical medical_review\">&quot;Arsenic exposure and poisoning&quot;</a>.)</p><p>The metabolites of <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">arsenic trioxide</a> are primarily excreted in the urine. Drug exposure may be higher in patients with severe renal impairment (creatine clearance [CrCl] &lt;30 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/133\" class=\"abstract_t\">133</a>]. While the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dec51fab-3784-deb7-752f-2d4d5692a20f&amp;token=6PR1JUORXIyDm7gLC03XrdiRECt/uql1aImMjeZ/H42JU7CbVa8Cai/jWU5BZrb8ZA7fDRffudMFtYTcVzUVvpFGxNUzM+y+vYCLpUe7szcs0pZXEoak/W4Yfrdt+571&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for arsenic trioxide and <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines provide no specific recommendations, both suggest that patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> should be closely monitored for toxicity during treatment and that a dose reduction may be warranted. The use of this drug in patients on dialysis has not been studied.</p><p class=\"headingAnchor\" id=\"H3207277281\"><span class=\"h2\">Etoposide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urinary excretion accounts for approximately 20 to 40 percent of each administered dose of <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/134\" class=\"abstract_t\">134</a>]. Renal insufficiency has been associated with increased exposure and higher levels of hematologic toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/135,136\" class=\"abstract_t\">135,136</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f850eb2-3542-43a0-90e8-bb37fa05cf15&amp;token=aHb1kJbWJahKvmaSMakTD4eMYwHhYsPVRYuaB25THAJXWxfBrWlxABzNUTsoyqliGL4herbfe2cyPLEjn3tCx1g+K+v2jzGZKygHIZ8MEHu0N3QsvI2Spj9othtm5Ks6&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> recommends a 25 percent reduction if the CrCl is 15 to 50 <span class=\"nowrap\">mL/min,</span> and that further dose reduction may be needed for more severe renal dysfunction. <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines are similar, although they recommend a 50 percent dose reduction or drug discontinuation if the CrCl is &lt;15 <span class=\"nowrap\">mL/min</span>.</p><p>Different guidelines are available from others:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For adults, Aronoff recommends a 25 percent dose reduction with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 50 percent reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kintzel recommends a 15 percent dose reduction for CrCl 46 to 60 <span class=\"nowrap\">mL/min,</span> a 20 percent dose reduction for CrCl 31 to 45 <span class=\"nowrap\">mL/min,</span> and a 25 percent dose reduction for CrCl &le;30 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p>Several case reports note the safe use of <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> in patients undergoing hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/106,121,137\" class=\"abstract_t\">106,121,137</a>]. Available guidelines suggest a 50 percent dose reduction, with administration either before or after dialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,10\" class=\"abstract_t\">8,10</a>]. In patients undergoing peritoneal dialysis, some clinicians recommend a 50 percent dose reduction [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H2349127310\"><span class=\"h2\">Irinotecan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After administration, <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> is enzymatically converted to an active metabolite, SN-38. Urinary excretion of irinotecan and SN-38 accounts for &lt;20 percent of drug elimination [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/138\" class=\"abstract_t\">138</a>].</p><p>There are conflicting data on whether <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> doses require modification in patients with renal insufficiency. Whereas the kidneys are responsible for only a small fraction of drug clearance and only small amounts of irinotecan have been recovered in urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/139\" class=\"abstract_t\">139</a>], several reports note excess toxicity in patients with end-stage renal disease, even with reduced doses [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/140-144\" class=\"abstract_t\">140-144</a>]. Excess toxicity has been attributed to higher exposure to SN-38 [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/143\" class=\"abstract_t\">143</a>].</p><p>There are no formal guidelines for dose reduction in the setting of renal disease. Neither the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af&amp;token=9GjH1G9Um7yizb9lvFce5mIjOADI+gnm1/lrojL5oCFkSNWLqgzUT0UAIjiRFdOsezgVurv8cZRDvW4QK7UVWaWWZUnVf4aFumhYFkPSIY81Q3C0EgwBqo2tiw5P1ql1&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> nor <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> contains dose adjustment guidelines for patients with renal insufficiency. The United States prescribing information states that <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">irinotecan</a> is not recommended for use in patients on dialysis. However, in such patients, a review of published cases suggests that weekly doses of 50 to 80 <span class=\"nowrap\">mg/m<sup>2</sup></span> are generally tolerated, whereas even single doses of &gt;125 <span class=\"nowrap\">mg/m<sup>2</sup></span> have been associated with severe adverse events [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/143\" class=\"abstract_t\">143</a>]. Largely based on this experience, some authors suggest that patients undergoing hemodialysis receive initial doses of 50 <span class=\"nowrap\">mg/m<sup>2</sup></span> weekly, preferably after hemodialysis sessions or on nondialysis days [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"abstract_t\">10</a>]. There are no specific guidelines in patients undergoing peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Topotecan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">Topotecan</a> is predominantly cleared by the kidneys, and increased toxicity may be seen in patients with moderate renal insufficiency [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8,145\" class=\"abstract_t\">8,145</a>]. Specific guidelines for dose reduction from expert groups differ:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=140399d0-4b28-4100-b792-3d1aa3c3e29c&amp;token=3PiOMD1tPk423AVXI3YLkbcccmWYQVV9ShNjsOz0KwlChwq6fZI8wQtFVUu6B6+6Nup/JiD266G774YmblwgXlC0HqI9xBkJMA2lPLTX3ogAfvnNv7QWqzcEnhwI62Yv&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for intravenous <a href=\"topic.htm?path=topotecan-drug-information\" class=\"drug drug_general\">topotecan</a> recommends a 50 percent reduction in the initial dose for CrCl 20 to 39 <span class=\"nowrap\">mL/min;</span> there are insufficient data to provide a dose recommendation for those with more severe impairment. For oral topotecan, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=140399d0-4b28-4100-b792-3d1aa3c3e29c&amp;token=JCwbYtFq9gvX1TaZd/2ZPVGrou2pJUVVavspuM9K1hfoUHKo2h2BXDjFN+pfnIx7F8bIL3BdYE664JH3W9//0IN/aYwFLyPGNRuRfjLbynzyju70T+dGan8GQmEzSRxZ&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> suggests a reduction in the initial dose from 2.3 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day to 1.5 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day for CrCl 30 to 49 <span class=\"nowrap\">mL/min</span> and a reduction to 0.6 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day for CrCl &lt;30 <span class=\"nowrap\">mL/min</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> guidelines suggest a 50 percent dose reduction for CrCl 20 to 39 <span class=\"nowrap\">mL/min</span> and that the drug be avoided with more severe renal impairment. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For adults, Aronoff suggests a 50 percent dose reduction for patients with CrCl 10 to 50 <span class=\"nowrap\">mL/min</span> and a 75 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/8\" class=\"abstract_t\">8</a>]. Avoid use in hemodialysis patients and in those receiving continuous ambulatory peritoneal dialysis; give a reduced dose (0.75 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> for continuous renal replacement therapy. For children, a 25 percent dose reduction is recommended for CrCl 30 to 50 <span class=\"nowrap\">mL/min,</span> a 50 percent dose reduction for CrCl 10 to 29 <span class=\"nowrap\">mL/min,</span> and a 75 percent dose reduction for CrCl &lt;10 <span class=\"nowrap\">mL/min</span>. For continuous renal replacement therapy, give a 50 percent reduced dose.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kintzel recommends a 20 percent dose reduction for CrCl 46 to 60 <span class=\"nowrap\">mL/min,</span> a 25 percent dose reduction for CrCl 31 to 45 <span class=\"nowrap\">mL/min,</span> and a 30 percent dose reduction for CrCl &le;30 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"headingAnchor\" id=\"H506101819\"><span class=\"h1\">IMMUNOMODULATORY DRUGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunomodulatory imide drugs (IMiDs), which include <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a>, <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a>, and <a href=\"topic.htm?path=pomalidomide-drug-information\" class=\"drug drug_general\">pomalidomide</a>, are used for the treatment of relapsed or recurrent multiple myeloma, a disease that frequently is associated with renal impairment. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma#H6107453\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory multiple myeloma&quot;, section on 'Immunomodulatory drugs'</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-etiology-of-kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and etiology of kidney disease in multiple myeloma and other monoclonal gammopathies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1094509837\"><span class=\"h2\">Thalidomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">Thalidomide</a>, a first-generation IMiD, is metabolized&nbsp;via&nbsp;nonenzymatic hydrolysis, and &lt;1 percent of the unchanged drug is excreted in the urine [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/146\" class=\"abstract_t\">146</a>]. In the initial report showing thalidomide activity against multiple myeloma, 8 out of 84 patients had a &gt;50 percent increase in serum creatinine; however, the kidney injury was attributed to underlying disease progression and not drug-related toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/147\" class=\"abstract_t\">147</a>]. In clinical practice, the use of thalidomide has not been associated with clinically significant acute kidney injury. However, there are reports of otherwise unexplained hyperkalemia in patients with myeloma treated with thalidomide [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/148,149\" class=\"abstract_t\">148,149</a>].</p><p>Dose adjustment is not necessary for patients with renal impairment, including those on dialysis. However, close monitoring of potassium levels is prudent for such individuals.</p><p class=\"headingAnchor\" id=\"H1008634410\"><span class=\"h2\">Lenalidomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">Lenalidomide</a> is an analog of <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> that, in contrast to thalidomide, is predominantly excreted in the urine as unchanged drug. The half-life and area under the curve of concentration X time (AUC) for lenalidomide increase as creatine clearance (CrCl) decreases [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/150\" class=\"abstract_t\">150</a>]. As a result, patients with preexisting renal insufficiency are at risk for increased drug toxicity [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/151,152\" class=\"abstract_t\">151,152</a>]. In one analysis of 72 patients with multiple myeloma who were treated with lenalidomide plus <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, individuals with CrCl &lt;40 <span class=\"nowrap\">mL/min</span> had an 8.4-fold higher likelihood of requiring a lenalidomide dose reduction for grade 3 or worse myelosuppression [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/151\" class=\"abstract_t\">151</a>]. </p><p>Cases of lenalidomide-induced acute kidney injury have been reported, including a case of biopsy-proven acute interstitial nephritis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/153,154\" class=\"abstract_t\">153,154</a>]. In a series of 41 patients with immunoglobulin light chain amyloidosis who were treated with <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a>, 27 (66 percent) developed kidney dysfunction (defined as a &ge;50 percent increase in serum creatinine) during treatment, including four of the eight patients without underlying renal amyloidosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/155\" class=\"abstract_t\">155</a>]. Severe renal dysfunction occurred in 13 patients (32 percent), four of whom required dialysis. The median time to kidney dysfunction after starting lenalidomide was 44 days (interquartile range 15 to 108 days).</p><p>Other types of renal toxicity have been reported, but they seem to be rare overall:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At least one patient has developed Fanconi syndrome (generalized proximal tubular dysfunction characterized by phosphaturia, renal glucosuria, aminoaciduria, tubular proteinuria, and proximal renal tubular acidosis) while receiving <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/156\" class=\"abstract_t\">156</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One patient has been described with acute interstitial nephritis and a drug reaction with eosinophilia, rash, and systemic symptoms (DRESS syndrome) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/157\" class=\"abstract_t\">157</a>]. (See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A case of minimal change disease was reported in a patient with Waldenstr&ouml;m macroglobulinemia being treated with <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/158\" class=\"abstract_t\">158</a>]. </p><p/><p class=\"bulletIndent1\">The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be&amp;token=I/RrX3Co70LVhOOM3DPf6LZs/WcCv2jCqYho7nyJ9Ko/JOMqrrckXtGTPfaBSm2ZQUxhhskHVXEHuf4G7tHJpxcbyZPyv7OQ/vVFPs+BBVpbBUl8Y0KGgaYKtpeuvSwC&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> recommends the following dose reduction strategy for individuals treated for multiple myeloma or mantle cell lymphoma who have preexisting renal disease: </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 30 to 60 <span class=\"nowrap\">mL/min</span> &ndash; Reduce the initial dose from 25 mg once daily to 10 mg once daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 15 to 30 <span class=\"nowrap\">mL/min</span> &ndash; Reduce the initial dose to 15 mg once every other day </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl &lt;15 <span class=\"nowrap\">mL/min</span> or end-stage renal disease on dialysis &ndash; Reduce the initial dose to 5 mg once daily (on dialysis days, the dose should be administered after dialysis)</p><p/><p>Separate guidelines are provided for patients receiving <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> for treatment of myelodysplastic syndrome and for maintenance treatment of myeloma following autologous stem cell transplantation:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 30 to 60 <span class=\"nowrap\">mL/min</span> &ndash; 5 mg once daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 15 to 30 <span class=\"nowrap\">mL/min</span> (nondialysis dependent) &ndash; 2.5 mg once daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl &lt;15 <span class=\"nowrap\">mL/min</span> or dialysis dependent &ndash; 2.5 mg once daily (on dialysis days, the drug should be administered after dialysis)</p><p/><p>These recommendations for <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> dose reduction during treatment with lenalidomide plus <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> for multiple myeloma are also endorsed by the International Myeloma Working Group (IMWG) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"abstract_t\">159</a>] and <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>. </p><p>Slightly different dose reduction guidelines are available from <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> for patients receiving <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> for myelodysplastic syndrome: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl 30 to 59 <span class=\"nowrap\">mL/min</span> &ndash; 5 mg once daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl &lt;30 <span class=\"nowrap\">mL/min</span> not requiring dialysis &ndash; 5 mg every other day</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CrCl &lt;30 <span class=\"nowrap\">mL/min</span> requiring dialysis &ndash; 5 mg three times a week following dialysis</p><p/><p>There are no specific dosing guidelines for <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> in patients on peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H2639602196\"><span class=\"h2\">Pomalidomide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pomalidomide-drug-information\" class=\"drug drug_general\">Pomalidomide</a> is a second-generation IMiD that is predominantly metabolized by the liver. In one of the three trials that evaluated its efficacy in multiple myeloma, the incidence of grade 3 to 4 renal toxicity (<a href=\"image.htm?imageKey=HEME%2F91253\" class=\"graphic graphic_table graphicRef91253 \">table 2</a>) was 5.9 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/160\" class=\"abstract_t\">160</a>]. In addition, a single case of acute kidney injury with crystal nephropathy was attributed to pomalidomide; however, the confounding factors included concurrent use of <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a>, which may have contributed to both the acute kidney injury and the crystal formation [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/161\" class=\"abstract_t\">161</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;token=DFin70cocGSNWPLqImZZW+9PbxwE4y+We6Fta/bbAn/gdy6O16QKqpEXWp86SYvrG9fqkoxkvLCxXsT57M3UbMPmxZXDM4KgMwLz05E9pmO6uT2Gwa1o6XMw0gGjBZ2s&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for <a href=\"topic.htm?path=pomalidomide-drug-information\" class=\"drug drug_general\">pomalidomide</a> provides no dose adjustments for patients with preexisting renal impairment, except for those on hemodialysis, who require initial dose reduction (recommended starting dose 3 mg daily); on dialysis days, the drug should be administered after hemodialysis. The same recommendation is endorsed by <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>. The IMWG recommends no dose adjustments for individuals with CrCl &ge;45 <span class=\"nowrap\">mL/min</span> but states that there are insufficient data for individuals with CrCl &lt;45 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"abstract_t\">159</a>].</p><p class=\"headingAnchor\" id=\"H4288371595\"><span class=\"h1\">PROTEASOME INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Proteasome inhibitors block the action of proteasomes, which are enzyme complexes responsible for the degradation of intracellular proteins. These agents have been approved for use in the treatment of multiple myeloma. (See <a href=\"topic.htm?path=selection-of-initial-chemotherapy-for-symptomatic-multiple-myeloma\" class=\"medical medical_review\">&quot;Selection of initial chemotherapy for symptomatic multiple myeloma&quot;</a> and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory multiple myeloma&quot;</a> and <a href=\"topic.htm?path=treatment-protocols-for-multiple-myeloma\" class=\"medical medical_review\">&quot;Treatment protocols for multiple myeloma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1287551229\"><span class=\"h2\">Bortezomib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, nephrotoxicity is uncommon with <a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">bortezomib</a>, although several cases of thrombotic microangiopathy (TMA) have been reported. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H1200899537\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Proteasome inhibitors'</a>.)</p><p>In addition, a case of biopsy-proven acute interstitial nephritis with granuloma formation has been described [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/162\" class=\"abstract_t\">162</a>].</p><p>The <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7&amp;token=GaqjZ8PFhh1JhXMojtsPMDQkSGVgvfol6252gjYR4h1tEnKjHn2ay8CRu/GN+AQYq08dl8x/P6kE0zu7KXI0+W8Ich1iMIO1SqMJ5xnJVAFAsbc9mHI5BP2opX70Js7H&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> as well as guidelines from <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> and the International Myeloma Working Group (IMWG) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"abstract_t\">159</a>] all state that no dose adjustment is necessary for patients with renal impairment, including those on dialysis. For hemodialysis patients, <a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">bortezomib</a> should be administered after dialysis since dialysis may reduce bortezomib concentrations [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/163\" class=\"abstract_t\">163</a>]. There are no specific guidelines for patients undergoing peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H2293233490\"><span class=\"h2\">Carfilzomib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been reports of creatinine elevations in up to 25 percent of patients treated with <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a phase II study of 266 patients with relapsed and refractory myeloma treated with single-agent <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a>, acute kidney injury was reported in 25 percent [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/164\" class=\"abstract_t\">164</a>]. Although the majority of renal adverse effects were mild, progressive kidney disease occurred in 3.8 percent of patients, leading to discontinuation of the drug in two patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another phase III trial of patients with relapsed or refractory multiple myeloma who received <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a> or a control regimen of low-dose glucocorticoids with optional <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, the incidence of grade 3 acute kidney injury (<a href=\"image.htm?imageKey=HEME%2F91253\" class=\"graphic graphic_table graphicRef91253 \">table 2</a>) was higher in the carfilzomib arm (8 versus 3 percent) [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/165\" class=\"abstract_t\">165</a>]. Renal adverse events of any type also occurred more frequently in the carfilzomib group (24 versus 9 percent); in both groups, these events were more likely to occur among patients with lower creatinine clearance (CrCl; &lt;30 <span class=\"nowrap\">mL/min)</span> and in those with evidence of a urine monoclonal protein. </p><p/><p>Potential mechanisms for acute kidney injury in patients treated with <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a> include prerenal causes (eg, hypovolemia), tumor lysis-like syndrome, or acute tubular necrosis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/166-171\" class=\"abstract_t\">166-171</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-etiology-of-kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies#H2348744349\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and etiology of kidney disease in multiple myeloma and other monoclonal gammopathies&quot;, section on 'Antimyeloma agents'</a> and <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H1200899537\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Proteasome inhibitors'</a>.) </p><p>TMA has also been described in patients treated with <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a>. In one case series, the median time between drug initiation and diagnosis was 21 days (range 5 days to 17 months), and the majority had complete resolution of TMA after discontinuation of the proteasome inhibitor [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/172\" class=\"abstract_t\">172</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H1200899537\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Proteasome inhibitors'</a>.)</p><p>The pharmacokinetics and safety of <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a> are not altered by preexisting renal impairment, including in patients on hemodialysis [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/173,174\" class=\"abstract_t\">173,174</a>]. Both the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6&amp;token=gH1mZVvRofJg1pa9gDqZTLEHynBlcoZ4/JV3Nj0p6xjLRuDK7LVHu+tXFG7pyGMe6HJMQUGNdOfZBkFMpSxKq6Sa9dR3IwcF/VJgR2W1tuJLceyPVOC01+xNkfNB1JKA&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> and guidelines from <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> state that dose adjustments are not required for patients with preexisting mild, moderate, or severe renal impairment, including those on dialysis. The IMWG suggests that carfilzomib can be safely administered to patients with CrCl &ge;15 <span class=\"nowrap\">mL/min;</span> although there are fewer data, carfilzomib may also be administered to patients with CrCl &lt;15 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"abstract_t\">159</a>]. In hemodialysis patients, carfilzomib should be administered after dialysis.</p><p>For patients who develop renal toxicity during treatment with <a href=\"topic.htm?path=carfilzomib-drug-information\" class=\"drug drug_general\">carfilzomib</a>, the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6&amp;token=gH1mZVvRofJg1pa9gDqZTLEHynBlcoZ4/JV3Nj0p6xjLRuDK7LVHu+tXFG7pyGMe6HJMQUGNdOfZBkFMpSxKq6Sa9dR3IwcF/VJgR2W1tuJLceyPVOC01+xNkfNB1JKA&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> provides specific guidelines for management of the dose. If<strong> </strong>serum creatinine is &ge;2 times baseline, CrCl is &lt;15 <span class=\"nowrap\">mL/min</span> or decreases to &le;50 percent of baseline, or the patient requires dialysis, one should withhold the dose and monitor renal function. If renal toxicity is attributable to carfilzomib, resume dosing when renal function has improved to within 25 percent of baseline; resume with a one-dose-level reduction. If toxicity is not due to carfilzomib, dosing may be resumed at the discretion of the prescriber. These guidelines are also endorsed by <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a>.</p><p class=\"headingAnchor\" id=\"H3595030606\"><span class=\"h2\">Ixazomib</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ixazomib-drug-information\" class=\"drug drug_general\">Ixazomib</a> is an orally active proteasome inhibitor; as with other proteasome inhibitors, TMA has been reported rarely [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/175\" class=\"abstract_t\">175</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H1200899537\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Proteasome inhibitors'</a>.)</p><p><a href=\"topic.htm?path=ixazomib-drug-information\" class=\"drug drug_general\">Ixazomib</a> is predominantly excreted in the urine, and initial dose adjustment is needed in patients with severe renal impairment. Both the <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcef9088-ebab-4bd8-933f-c35f9c8bd50b&amp;token=CDr8dxcHNs7XAMuGv0H4eAlCrCLBCLiQnh0Mrbuxwpkn5rwYFT11WlKzXccpdyXHPQzho4lcBcucpgLY+8aqdgCxJqVDET89C+bUOkOkFDokL6YVFukYUd4Yn/cxxya8&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">United States prescribing information</a> for ixazomib and guidelines from <a href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760&amp;token=R4Uiw8/bmPVaqNHRDqpXLKwIuYnRT9PFkjEECHZit2JQ/DDrLUr1+Fl78Tz4sF+JiPOKwEVJ7lkqc5lswInA/+mqPm/qTjRCCcN3RAaTFdE=&amp;TOPIC_ID=2834\" target=\"_blank\" class=\"external\">Cancer Care Ontario</a> recommend reducing the starting dose from 4 mg once weekly to 3 mg once weekly in patients with CrCl &lt;30 <span class=\"nowrap\">mL/min</span> or end-stage renal disease requiring dialysis (CrCl &lt;30 <span class=\"nowrap\">mL/min)</span>. IMWG guidelines state only that ixazomib can be safely administered in combination with <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> and <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> in patients with CrCl &ge;30 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"abstract_t\">159</a>].</p><p>For patients with end-stage renal disease, <a href=\"topic.htm?path=ixazomib-drug-information\" class=\"drug drug_general\">ixazomib</a> is not dialyzable and can be administered without regard for the timing of dialysis.</p><p class=\"headingAnchor\" id=\"H42\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cytotoxic chemotherapy can cause renal toxicity through a number of mechanisms. Several factors can potentiate renal dysfunction and contribute to the nephrotoxic potential of antineoplastic drugs. These include intravascular volume depletion, the concomitant use of nonchemotherapeutic nephrotoxic drugs (eg, aminoglycoside antibiotics, nonsteroidal antiinflammatory drugs) or radiographic ionic contrast media in patients with or without preexisting renal dysfunction, tumor-related urinary tract obstruction, and intrinsic renal disease that is idiopathic, related to other comorbidities, or related to the cancer itself. (See <a href=\"#H3\" class=\"local\">'Risk factors for nephrotoxicity'</a> above.)</p><p/><p class=\"bulletIndent1\">These factors should be considered by the treating oncologist before initiating treatment in order to minimize the risk of excessive toxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For those drugs in which renal excretion is an important determinant of elimination of the intact drug or an active metabolite, renal impairment can alter excretion and increase systemic toxicity. Dose adjustment is often required.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most commonly used chemotherapeutic agents for which dose modification may be needed in the setting of renal insufficiency are listed in the table (<a href=\"image.htm?imageKey=ONC%2F56245\" class=\"graphic graphic_table graphicRef56245 \">table 1</a>).</p><p/><p class=\"bulletIndent1\">Dose adjustment in this setting is typically based upon two factors: an estimation of glomerular filtration rate (GFR), which serves as an index of the number of functioning nephrons, and evaluation of clinical signs of drug toxicity (eg, neutropenia, thrombocytopenia). The available data in cancer patients suggest that all bedside formula for estimating GFR provide similar levels of concordance when used for the purpose of dosing renally excreted cancer drugs. (See <a href=\"#H2\" class=\"local\">'Estimation of GFR for possible dose adjustment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minimizing nonrenal systemic toxicity in patients receiving chemotherapy may be a particular problem in patients on chronic hemodialysis, especially when the details of drug elimination and metabolism are not fully known [<a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/9\" class=\"abstract_t\">9</a>]. For patients undergoing dialysis, two issues must be considered (see <a href=\"#H263265423\" class=\"local\">'Drug handling in dialysis patients'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Since the kidneys are no longer functioning, dose reduction may be needed to avoid overexposure and drug toxicity.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Drug clearance by dialysis must be taken into account for appropriate timing of chemotherapy in patients treated with hemodialysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following issues are pertinent to the dosing of <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a>, which is uniquely based upon estimated GFR:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For most patients, <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> dosing uses the Calvert formula, which is based upon desired exposure (area under the curve of concentration X time [AUC]) and GFR. When GFR is estimated based upon measured serum creatinine, we suggest limiting the maximal GFR to 125 <span class=\"nowrap\">mL/min</span> for this calculation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This suggestion does not apply if the GFR is directly measured. (See <a href=\"#H787081390\" class=\"local\">'AUC dose calculation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When calculating <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> doses, actual weight should be used for estimation of GFR by the Cockcroft-Gault equation as long as patients have a body mass index (BMI) of &lt;25 (<a href=\"topic.htm?path=calculator-body-mass-index-bmi-quetelets-index-in-adults\" class=\"calc calc_professional\">calculator 5</a>). For other patients, use of an adjusted weight is suggested (adjusted weight [kg] = [(actual weight - ideal weight) x 0.40] + ideal weight). A calculator for ideal body weight is available (<a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" class=\"calc calc_professional\">calculator 6</a>).</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/1\" class=\"nounderline abstract_t\">Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/2\" class=\"nounderline abstract_t\">Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30:548.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/3\" class=\"nounderline abstract_t\">Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/4\" class=\"nounderline abstract_t\">Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/5\" class=\"nounderline abstract_t\">Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol 2013; 24:2746.</a></li><li class=\"breakAll\">https://www.abbottpointofcare.com/download?docUri=/technical-library/static-assets/technical-documentation/714183-00Y.pdf (Accessed on November 04, 2016).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/7\" class=\"nounderline abstract_t\">Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14.</a></li><li class=\"breakAll\">Aronoff GM, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th, American College of Physicians, 2007.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/9\" class=\"nounderline abstract_t\">Boesler B, Czock D, Keller F, et al. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 2005; 20:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/10\" class=\"nounderline abstract_t\">Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21:1395.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/11\" class=\"nounderline abstract_t\">Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010; 66:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/12\" class=\"nounderline abstract_t\">Nordstrom BL, Knopf KB, Teltsch DY, et al. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. Leuk Lymphoma 2014; 55:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/13\" class=\"nounderline abstract_t\">DeFronzo RA, Colvin OM, Braine H, et al. Proceedings: Cyclophosphamide and the kidney. Cancer 1974; 33:483.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/14\" class=\"nounderline abstract_t\">Bode U, Seif SM, Levine AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol 1980; 8:295.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/15\" class=\"nounderline abstract_t\">Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/16\" class=\"nounderline abstract_t\">Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21:33.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/17\" class=\"nounderline abstract_t\">Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979; 3:253.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/18\" class=\"nounderline abstract_t\">Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61:1495.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/19\" class=\"nounderline abstract_t\">Jank&#367; I, Modr Z, Krebs V. A set of simple aids to drug dosage adjustment in renal insufficiency. Int J Clin Pharmacol Ther Toxicol 1990; 28:27.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/20\" class=\"nounderline abstract_t\">Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant 1999; 23:839.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/21\" class=\"nounderline abstract_t\">Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer 2012; 48:1326.</a></li><li class=\"breakAll\">Renal pharmacotherapy: Dosage adjustment of medications eliminated by the kidneys., Golightly L, Teitelbaum I, Kizer TH, et al. (Eds), Springer, New York 2013.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/23\" class=\"nounderline abstract_t\">Latcha S, Maki RG, Schwartz GK, Flombaum CD. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009; 2009:575629.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/24\" class=\"nounderline abstract_t\">Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, et al. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. Cancer 1985; 55:44.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/25\" class=\"nounderline abstract_t\">Helson L, Sadof MD, Wernovsky G, Gulati S. L-phenylalanine mustard-dianhydrogalactitol and hyponatremia. Pediatr Hematol Oncol 1986; 3:287.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/26\" class=\"nounderline abstract_t\">Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/27\" class=\"nounderline abstract_t\">Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005; 128:631.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/28\" class=\"nounderline abstract_t\">Batalini F, Econimo L, Quillen K, et al. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant 2018; 24:127.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/29\" class=\"nounderline abstract_t\">Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE. Chronic renal failure in children treated with methyl CCNU. N Engl J Med 1979; 300:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/30\" class=\"nounderline abstract_t\">Narins RG, Carley M, Bloom EJ, Harrison DS. The nephrotoxicity of chemotherapeutic agents. Semin Nephrol 1990; 10:556.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/31\" class=\"nounderline abstract_t\">Sponzo RW, DeVita VT, Oliverio VT. Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. Cancer 1973; 31:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/32\" class=\"nounderline abstract_t\">Schacht RG, Feiner HD, Gallo GR, et al. Nephrotoxicity of nitrosoureas. Cancer 1981; 48:1328.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/33\" class=\"nounderline abstract_t\">Sadoff L. Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother Rep 1970; 54:457.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/34\" class=\"nounderline abstract_t\">Myerowitz RL, Sartiano GP, Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin: report of a patient with multiple hormone-secreting islet cell carcinoma. Cancer 1976; 38:1550.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/35\" class=\"nounderline abstract_t\">Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84:153.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/36\" class=\"nounderline abstract_t\">Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987; 9:79.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/37\" class=\"nounderline abstract_t\">Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/38\" class=\"nounderline abstract_t\">Tobin MV, Warenius HM, Morris AI. Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma. Br Med J (Clin Res Ed) 1987; 294:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/39\" class=\"nounderline abstract_t\">Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/40\" class=\"nounderline abstract_t\">Armstrong AE, Dargart J, Reichek J, et al. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer 2014; 61:949.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/41\" class=\"nounderline abstract_t\">Pick AM, Nystrom KK. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. J Oncol Pharm Pract 2010; 16:269.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/42\" class=\"nounderline abstract_t\">Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther 2007; 6:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/43\" class=\"nounderline abstract_t\">Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001; 7:231.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/44\" class=\"nounderline abstract_t\">Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/45\" class=\"nounderline abstract_t\">Stoyianni A, Kapodistrias N, Kampletsas E, et al. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 2011; 97:252.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/46\" class=\"nounderline abstract_t\">Moe MM, Fernandez Teruel C, Soto-Matos A. Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failure. Chemotherapy 2013; 59:458.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/47\" class=\"nounderline abstract_t\">Thariat J, Etienne-Grimaldi MC, Launay-Vacher V, et al. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. Cancer Chemother Pharmacol 2011; 68:1363.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/48\" class=\"nounderline abstract_t\">Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49:225.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/49\" class=\"nounderline abstract_t\">Jhaveri KD, Flombaum C, Shah M, Latcha S. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR &lt;30 mL/min) and end stage renal disease on hemodialysis. J Oncol Pharm Pract 2012; 18:140.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/50\" class=\"nounderline abstract_t\">Jhaveri KD, Chidella S, Allen SL, Fishbane S. Clofarabine-induced kidney toxicity. J Oncol Pharm Pract 2014; 20:305.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/51\" class=\"nounderline abstract_t\">Kintzel PE, Visser JA, Campbell AD. Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 2011; 31:923.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/52\" class=\"nounderline abstract_t\">Petri CR, O'Donnell PH, Cao H, et al. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma 2014; 55:2866.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/53\" class=\"nounderline abstract_t\">Bonate PL, Cunningham CC, Gaynon P, et al. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol 2011; 67:875.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/54\" class=\"nounderline abstract_t\">Bonate PL, Craig A, Gaynon P, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004; 44:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/55\" class=\"nounderline abstract_t\">Benitez LL, Gharibian K, Frame D, et al. Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature. J Pediatr Hematol Oncol 2017; 39:481.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/56\" class=\"nounderline abstract_t\">Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15:833.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/57\" class=\"nounderline abstract_t\">Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest 2002; 20:904.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/58\" class=\"nounderline abstract_t\">Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32:120.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/59\" class=\"nounderline abstract_t\">Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21:3038.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/60\" class=\"nounderline abstract_t\">Glezerman I, Kris MG, Miller V, et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 2009; 71:130.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/61\" class=\"nounderline abstract_t\">Saif MW, Xyla V, Makrilia N, et al. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009; 8:257.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/62\" class=\"nounderline abstract_t\">Leal F, Macedo LT, Carvalheira JB. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother 2014; 26:169.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/63\" class=\"nounderline abstract_t\">Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/64\" class=\"nounderline abstract_t\">Kiani A, K&ouml;hne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003; 51:266.</a></li><li class=\"breakAll\">Matsuda M. Gemcitabine for patients with chronic renal failure on hemodialysis (abstract #15189). J Clin Oncol 2007; 25:15189.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/66\" class=\"nounderline abstract_t\">Wiczling P, Liem RI, Panepinto JA, et al. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. J Clin Pharmacol 2014; 54:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/67\" class=\"nounderline abstract_t\">Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998; 34:347.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/68\" class=\"nounderline abstract_t\">Howell SB, Carmody J. Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 1977; 61:1389.</a></li><li class=\"breakAll\">Schilsky RL. Renal and metabolic toxicities of cancer treatment. In: Toxicity of chemotherapy, Perry MC, Yarbro JW (Eds), Grune &amp; Stratton, Philadelphi 1984. p.317.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/70\" class=\"nounderline abstract_t\">Bowyer GW, Davies TW. Methotrexate toxicity associated with an ileal conduit. Br J Urol 1987; 60:592.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/71\" class=\"nounderline abstract_t\">Foss&aring; SD, Heilo A, B&oslash;rmer O. Unexpectedly high serum methotrexate levels in cystectomized bladder cancer patients with an ileal conduit treated with intermediate doses of the drug. J Urol 1990; 143:498.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/72\" class=\"nounderline abstract_t\">Martini A, Villari D, Nicita G. Long-term complications arising from bowel interposition in the urinary tract. Int J Surg 2017; 44:278.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/73\" class=\"nounderline abstract_t\">Liu WC, Chen HC, Chen JS. Clinical dilemma over low-dose methotrexate therapy in dialysis patients: a case report and review of literature. Iran J Kidney Dis 2014; 8:81.</a></li><li class=\"breakAll\">Garrick, MB, Mayer, et al. Acute renal failure associated with cancer treatment. In: Acute Renal Failure, 2nd ed, Brenner, BM, Lazarus, JM (Eds), Churchill Livingstone, New York 1988. p.636.</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/75\" class=\"nounderline abstract_t\">Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/76\" class=\"nounderline abstract_t\">Stavroulopoulos A, Nakopoulou L, Xydakis AM, et al. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 2010; 32:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/77\" class=\"nounderline abstract_t\">Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2006; 23:419.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/78\" class=\"nounderline abstract_t\">Zattera T, Londrino F, Trezzi M, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 2017; 6:43.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/79\" class=\"nounderline abstract_t\">Rombol&agrave; G, Vaira F, Trezzi M, et al. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage. J Nephrol 2015; 28:187.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/80\" class=\"nounderline abstract_t\">Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006; 24:552.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/81\" class=\"nounderline abstract_t\">Brogden RN, Sorkin EM. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993; 46:652.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/82\" class=\"nounderline abstract_t\">Lathia C, Fleming GF, Meyer M, et al. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol 2002; 50:121.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/83\" class=\"nounderline abstract_t\">Poi MJ, Hofmeister CC, Johnston JS, et al. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet 2013; 52:705.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/84\" class=\"nounderline abstract_t\">Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009; 86:190.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/85\" class=\"nounderline abstract_t\">Kelly KR, Gabrail N, Weitman S, et al. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol 2016; 78:929.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/86\" class=\"nounderline abstract_t\">Furuya Y, Takihana Y, Araki I, et al. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report]. Gan To Kagaku Ryoho 2003; 30:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/87\" class=\"nounderline abstract_t\">Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 2002; 84:335.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/88\" class=\"nounderline abstract_t\">Baur M, Fazeny-Doerner B, Olsen SJ, Dittrich C. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. Int J Gynecol Cancer 2008; 18:564.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/89\" class=\"nounderline abstract_t\">Heijns JB, van der Burg ME, van Gelder T, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol 2008; 62:841.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/90\" class=\"nounderline abstract_t\">Mencoboni M, Olivieri R, Vannozzi MO, et al. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Chemotherapy 2006; 52:147.</a></li><li class=\"breakAll\">US FDA labeling information for cabazitaxel available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19208 (Accessed on July 13, 2010).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/92\" class=\"nounderline abstract_t\">Cutting HO. Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy. Am J Med 1971; 51:269.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/93\" class=\"nounderline abstract_t\">Garrett CA, Simpson TA Jr. Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Ann Pharmacother 1998; 32:1306.</a></li><li class=\"breakAll\">Synold, TW, Tsao-Wei, DD, Quinn, DI, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial (abstract 2527). J clin Oncol 2010; 28:210s. Abstract available online at http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=49636 (Accessed on February 07, 2011).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/95\" class=\"nounderline abstract_t\">Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 2013; 61:778.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/96\" class=\"nounderline abstract_t\">Shavit L, Lifschitz MD, Gabizon A, et al. Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. Kidney Int 2014; 85:213.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/97\" class=\"nounderline abstract_t\">Kwa M, Baumgartner R, Shavit L, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 2012; 17:1534.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/98\" class=\"nounderline abstract_t\">Carron PL, Padilla M, Maurizi Balzan J. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int 2014; 18:846.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/99\" class=\"nounderline abstract_t\">Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/100\" class=\"nounderline abstract_t\">Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980; 64:921.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/101\" class=\"nounderline abstract_t\">McLeod BF, Lawrence HJ, Smith DW, et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 1987; 60:2617.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/102\" class=\"nounderline abstract_t\">Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology (Williston Park) 1992; 6:62.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/103\" class=\"nounderline abstract_t\">Crona DJ, Faso A, Nishijima TF, et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist 2017; 22:609.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/104\" class=\"nounderline abstract_t\">Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006; 24:3095.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/105\" class=\"nounderline abstract_t\">Tomita M, Kurata H, Aoki Y, et al. Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 2001; 12:485.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/106\" class=\"nounderline abstract_t\">Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003; 88:25.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/107\" class=\"nounderline abstract_t\">Ribrag V, Droz JP, Morizet J, et al. Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann Oncol 1993; 4:679.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/108\" class=\"nounderline abstract_t\">Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/109\" class=\"nounderline abstract_t\">McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 1991; 90:386.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/110\" class=\"nounderline abstract_t\">Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 1991; 5:97.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/111\" class=\"nounderline abstract_t\">Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994; 73:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/112\" class=\"nounderline abstract_t\">Tscherning C, Rubie H, Chancholle A, et al. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994; 73:1761.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/113\" class=\"nounderline abstract_t\">Welborn J, Meyers FJ, O'Grady LF. Renal salt wasting and carboplatinum. Ann Intern Med 1988; 108:640.</a></li><li class=\"breakAll\">http://nkdep.nih.gov/labprofessionals/Clinical_Laboratories.htm (Accessed on August 18, 2011).</li><li class=\"breakAll\">FDA safety alert available online at http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm228974.htm (Accessed on October 14, 2010).</li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/116\" class=\"nounderline abstract_t\">De Jonge ME, Math&ocirc;t RA, Van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 2002; 50:251.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/117\" class=\"nounderline abstract_t\">English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer 1996; 73:776.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/118\" class=\"nounderline abstract_t\">Chatelut E, Rostaing L, Gualano V, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 1994; 66:157.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/119\" class=\"nounderline abstract_t\">Motzer RJ, Niedzwiecki D, Isaacs M, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 1990; 27:234.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/120\" class=\"nounderline abstract_t\">Yanagawa H, Takishita Y, Bando H, et al. Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Res 1996; 16:533.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/121\" class=\"nounderline abstract_t\">Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004; 15:51.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/122\" class=\"nounderline abstract_t\">Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol 2004; 54:295.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/123\" class=\"nounderline abstract_t\">L&eacute;vi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/124\" class=\"nounderline abstract_t\">Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 2002; 13:1951.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/125\" class=\"nounderline abstract_t\">Labaye J, Sarret D, Duvic C, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant 2005; 20:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/126\" class=\"nounderline abstract_t\">Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 2010; 27:1425.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/127\" class=\"nounderline abstract_t\">Chollet P, Bensma&iuml;ne MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/128\" class=\"nounderline abstract_t\">Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6:1205.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/129\" class=\"nounderline abstract_t\">Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/130\" class=\"nounderline abstract_t\">Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 2011; 68:263.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/131\" class=\"nounderline abstract_t\">Robles-Osorio ML, Sabath-Silva E, Sabath E. Arsenic-mediated nephrotoxicity. Ren Fail 2015; 37:542.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/132\" class=\"nounderline abstract_t\">He H, An R, Hou J, Fu W. Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report. Front Med 2017; 11:284.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/133\" class=\"nounderline abstract_t\">Sweeney CJ, Takimoto C, Wood L, et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol 2010; 66:345.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/134\" class=\"nounderline abstract_t\">Hande KR, Wedlund PJ, Noone RM, et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984; 44:379.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/135\" class=\"nounderline abstract_t\">Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14:257.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/136\" class=\"nounderline abstract_t\">D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46:2566.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/137\" class=\"nounderline abstract_t\">Holthuis JJ, Van de Vyver FL, van Oort WJ, et al. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treat Rep 1985; 69:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/138\" class=\"nounderline abstract_t\">Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28:423.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/139\" class=\"nounderline abstract_t\">Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4:2747.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/140\" class=\"nounderline abstract_t\">V&eacute;nat-Bouvet L, Saint-Marcoux F, Lagarde C, et al. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Anticancer Drugs 2007; 18:977.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/141\" class=\"nounderline abstract_t\">Shinozaki E, Mizunuma N, Tanabe M, et al. [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer]. Gan To Kagaku Ryoho 2005; 32:397.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/142\" class=\"nounderline abstract_t\">Ashizawa T, Iwahori T, Yokoyama T, et al. Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer. Acta Med Okayama 2010; 64:19.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/143\" class=\"nounderline abstract_t\">Czock D, Rasche FM, Boesler B, et al. Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 2009; 43:363.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/144\" class=\"nounderline abstract_t\">Stemmler J, Weise A, Hacker U, et al. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 2002; 25:60.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/145\" class=\"nounderline abstract_t\">O'Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14:3062.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/146\" class=\"nounderline abstract_t\">Chung F, Lu J, Palmer BD, et al. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res 2004; 10:5949.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/147\" class=\"nounderline abstract_t\">Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/148\" class=\"nounderline abstract_t\">Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122:160.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/149\" class=\"nounderline abstract_t\">Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004; 125:96.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/150\" class=\"nounderline abstract_t\">Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/151\" class=\"nounderline abstract_t\">Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na&iuml;ve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138:640.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/152\" class=\"nounderline abstract_t\">Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116:3807.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/153\" class=\"nounderline abstract_t\">Lipson EJ, Huff CA, Holanda DG, et al. Lenalidomide-induced acute interstitial nephritis. Oncologist 2010; 15:961.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/154\" class=\"nounderline abstract_t\">Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49:1108.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/155\" class=\"nounderline abstract_t\">Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011; 26:881.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/156\" class=\"nounderline abstract_t\">Glezerman IG, Kewalramani T, Jhaveri K. Reversible Fanconi syndrome due to lenalidomide. NDT Plus 2008; 1:215.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/157\" class=\"nounderline abstract_t\">Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract 2014; 20:302.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/158\" class=\"nounderline abstract_t\">Jamme M, Galichon P, Hertig A. Minimal change disease and lenalidomide. Am J Kidney Dis 2013; 62:844.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/159\" class=\"nounderline abstract_t\">Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016; 34:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/160\" class=\"nounderline abstract_t\">Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123:1826.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/161\" class=\"nounderline abstract_t\">Baird P, Leung S, Hoang H, et al. A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. J Oncol Pharm Pract 2016; 22:357.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/162\" class=\"nounderline abstract_t\">Cheungpasitporn W, Leung N, Rajkumar SV, et al. Bortezomib-induced acute interstitial nephritis. Nephrol Dial Transplant 2015; 30:1225.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/163\" class=\"nounderline abstract_t\">Leal TB, Remick SC, Takimoto CH, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol 2011; 68:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/164\" class=\"nounderline abstract_t\">Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/165\" class=\"nounderline abstract_t\">H&aacute;jek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 2017; 31:107.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/166\" class=\"nounderline abstract_t\">Jhaveri KD, Chidella S, Varghese J, et al. Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol 2013; 11:604.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/167\" class=\"nounderline abstract_t\">Wanchoo R, Khan S, Kolitz JE, Jhaveri KD. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. J Oncol Pharm Pract 2015; 21:313.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/168\" class=\"nounderline abstract_t\">Shely RN, Ratliff PD. Carfilzomib-associated tumor lysis syndrome. Pharmacotherapy 2014; 34:e34.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/169\" class=\"nounderline abstract_t\">Liberman V, D'Agati VD, Masani NN, et al. Acute Tubular Necrosis in a Patient With&nbsp;Myeloma Treated With Carfilzomib. Kidney Int Rep 2016; 1:89.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/170\" class=\"nounderline abstract_t\">Sullivan MR, Danilov AV, Lansigan F, Dunbar NM. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher 2015; 30:308.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/171\" class=\"nounderline abstract_t\">Hobeika L, Self SE, Velez JC. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15:156.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/172\" class=\"nounderline abstract_t\">Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 2016; 91:E348.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/173\" class=\"nounderline abstract_t\">Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27:1707.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/174\" class=\"nounderline abstract_t\">Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol 2017; 79:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents/abstract/175\" class=\"nounderline abstract_t\">Yui JC, Dispenzieri A, Leung N. Ixazomib-induced thrombotic microangiopathy. Am J Hematol 2017; 92:E53.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2834 Version 72.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H42\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ESTIMATION OF GFR FOR POSSIBLE DOSE ADJUSTMENT</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">RISK FACTORS FOR NEPHROTOXICITY</a></li><li><a href=\"#H263265423\" id=\"outline-link-H263265423\">DRUG HANDLING IN DIALYSIS PATIENTS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">ALKYLATING AGENTS</a><ul><li><a href=\"#H10242529\" id=\"outline-link-H10242529\">Bendamustine</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Cyclophosphamide</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Ifosfamide</a></li><li><a href=\"#H2899775478\" id=\"outline-link-H2899775478\">Melphalan</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Nitrosoureas</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Temozolomide</a></li><li><a href=\"#H3085716384\" id=\"outline-link-H3085716384\">Trabectedin</a></li></ul></li><li><a href=\"#H4095103962\" id=\"outline-link-H4095103962\">ANTIMETABOLITES</a><ul><li><a href=\"#H702282824\" id=\"outline-link-H702282824\">Capecitabine</a></li><li><a href=\"#H3789765438\" id=\"outline-link-H3789765438\">Clofarabine</a></li><li><a href=\"#H1991902678\" id=\"outline-link-H1991902678\">Cytarabine</a></li><li><a href=\"#H178323790\" id=\"outline-link-H178323790\">Fludarabine and cladribine</a></li><li><a href=\"#H3822453368\" id=\"outline-link-H3822453368\">Gemcitabine</a></li><li><a href=\"#H935841151\" id=\"outline-link-H935841151\">Hydroxyurea</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Methotrexate</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Pemetrexed</a></li><li><a href=\"#H3902156842\" id=\"outline-link-H3902156842\">Pentostatin</a></li><li><a href=\"#H203227473\" id=\"outline-link-H203227473\">Pralatrexate</a></li></ul></li><li><a href=\"#H1949885050\" id=\"outline-link-H1949885050\">ANTIMICROTUBULE AGENTS</a><ul><li><a href=\"#H3285757041\" id=\"outline-link-H3285757041\">Taxanes</a></li><li><a href=\"#H531929894\" id=\"outline-link-H531929894\">Vinca alkaloids</a></li><li><a href=\"#H1117729775\" id=\"outline-link-H1117729775\">Eribulin</a></li></ul></li><li><a href=\"#H3369160442\" id=\"outline-link-H3369160442\">ANTITUMOR ANTIBIOTICS</a><ul><li><a href=\"#H1057052687\" id=\"outline-link-H1057052687\">Anthracyclines and related agents</a></li><li><a href=\"#H1161271807\" id=\"outline-link-H1161271807\">Bleomycin</a></li><li><a href=\"#H1646397459\" id=\"outline-link-H1646397459\">Mitomycin</a></li></ul></li><li><a href=\"#H4029653556\" id=\"outline-link-H4029653556\">PLATINUM AGENTS</a><ul><li><a href=\"#H3902995358\" id=\"outline-link-H3902995358\">Cisplatin</a></li><li><a href=\"#H4183676142\" id=\"outline-link-H4183676142\">Carboplatin</a><ul><li><a href=\"#H787081390\" id=\"outline-link-H787081390\">- AUC dose calculation</a></li><li><a href=\"#H574865793\" id=\"outline-link-H574865793\">- Use in dialysis</a></li></ul></li><li><a href=\"#H1539158543\" id=\"outline-link-H1539158543\">Oxaliplatin</a></li></ul></li><li><a href=\"#H3920114876\" id=\"outline-link-H3920114876\">MISCELLANEOUS CYTOTOXIC AGENTS</a><ul><li><a href=\"#H4016699895\" id=\"outline-link-H4016699895\">Arsenic trioxide</a></li><li><a href=\"#H3207277281\" id=\"outline-link-H3207277281\">Etoposide</a></li><li><a href=\"#H2349127310\" id=\"outline-link-H2349127310\">Irinotecan</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Topotecan</a></li></ul></li><li><a href=\"#H506101819\" id=\"outline-link-H506101819\">IMMUNOMODULATORY DRUGS</a><ul><li><a href=\"#H1094509837\" id=\"outline-link-H1094509837\">Thalidomide</a></li><li><a href=\"#H1008634410\" id=\"outline-link-H1008634410\">Lenalidomide</a></li><li><a href=\"#H2639602196\" id=\"outline-link-H2639602196\">Pomalidomide</a></li></ul></li><li><a href=\"#H4288371595\" id=\"outline-link-H4288371595\">PROTEASOME INHIBITORS</a><ul><li><a href=\"#H1287551229\" id=\"outline-link-H1287551229\">Bortezomib</a></li><li><a href=\"#H2293233490\" id=\"outline-link-H2293233490\">Carfilzomib</a></li><li><a href=\"#H3595030606\" id=\"outline-link-H3595030606\">Ixazomib</a></li></ul></li><li><a href=\"#H42\" id=\"outline-link-H42\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/2834|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/56245\" class=\"graphic graphic_table\">- Chemo dose adj renal</a></li><li><a href=\"image.htm?imageKey=HEME/91253\" class=\"graphic graphic_table\">- NCI CTCAE v5 acute kidney injury, creatinine increased</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Creatinine clearance estimate by Cockcroft-Gault equation in adults and older adolescents (age &ge;18 years)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years-si-units\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Creatinine clearance estimate by Cockcroft-Gault equation in adults and older adolescents (age &ge;18 years) (SI units)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-glomerular-filtration-rate-estimate-by-abbreviated-mdrd-study-equation-in-adults\" title=\"calculator 3\" class=\"calc calc_professional\">Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-glomerular-filtration-rate-estimate-by-ckd-epi-equation-in-adults\" title=\"calculator 4\" class=\"calc calc_professional\">Calculator: Glomerular filtration rate estimate by CKD-EPI equation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-body-mass-index-bmi-quetelets-index-in-adults\" title=\"calculator 5\" class=\"calc calc_professional\">Calculator: Body mass index (BMI; Quetelet's index) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" title=\"calculator 6\" class=\"calc calc_professional\">Calculator: Ideal body weight (method of Devine) and dosing weight for adults</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=arsenic-exposure-and-poisoning\" class=\"medical medical_review\">Arsenic exposure and poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-kidney-function\" class=\"medical medical_review\">Assessment of kidney function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bleomycin-induced-lung-injury\" class=\"medical medical_review\">Bleomycin-induced lung injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-in-castration-resistant-prostate-cancer\" class=\"medical medical_review\">Chemotherapy in castration-resistant prostate cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents\" class=\"medical medical_review\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cisplatin-nephrotoxicity\" class=\"medical medical_review\">Cisplatin nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">Crystal-induced acute kidney injury (acute renal failure)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystitis-in-patients-with-cancer\" class=\"medical medical_review\">Cystitis in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dosing-of-anticancer-agents-in-adults\" class=\"medical medical_review\">Dosing of anticancer agents in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-removal-in-continuous-renal-replacement-therapy\" class=\"medical medical_review\">Drug removal in continuous renal replacement therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-etiology-of-kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies\" class=\"medical medical_review\">Epidemiology, pathogenesis, and etiology of kidney disease in multiple myeloma and other monoclonal gammopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hydroxyurea-use-in-sickle-cell-disease\" class=\"medical medical_review\">Hydroxyurea use in sickle cell disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ifosfamide-nephrotoxicity\" class=\"medical medical_review\">Ifosfamide nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Initial treatment of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Kidney disease following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-primary-myelofibrosis\" class=\"medical medical_review\">Management of primary myelofibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nitrosourea-induced-pulmonary-injury\" class=\"medical medical_review\">Nitrosourea-induced pulmonary injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-kidney-disease-in-the-cancer-patient\" class=\"medical medical_review\">Overview of kidney disease in the cancer patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-contrast-induced-nephropathy\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-etiology-of-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh\" class=\"medical medical_review\">Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-essential-thrombocythemia\" class=\"medical medical_review\">Prognosis and treatment of essential thrombocythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-polycythemia-vera\" class=\"medical medical_review\">Prognosis and treatment of polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selection-of-initial-chemotherapy-for-symptomatic-multiple-myeloma\" class=\"medical medical_review\">Selection of initial chemotherapy for symptomatic multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation\" class=\"medical medical_review\">Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-unresectable-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Systemic treatment for unresectable malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy\" class=\"medical medical_review\">Systemic treatment of metastatic breast cancer in women: Chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma\" class=\"medical medical_review\">Systemic treatment of metastatic soft tissue sarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-aging-kidney\" class=\"medical medical_review\">The aging kidney</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-use-and-toxicity-of-high-dose-methotrexate\" class=\"medical medical_review\">Therapeutic use and toxicity of high-dose methotrexate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicities-associated-with-checkpoint-inhibitor-immunotherapy\" class=\"medical medical_review\">Toxicities associated with checkpoint inhibitor immunotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-t-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">Treatment of T cell prolymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acute-graft-versus-host-disease\" class=\"medical medical_review\">Treatment of acute graft-versus-host disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hairy-cell-leukemia\" class=\"medical medical_review\">Treatment of hairy cell leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hyponatremia-syndrome-of-inappropriate-antidiuretic-hormone-secretion-siadh-and-reset-osmostat\" class=\"medical medical_review\">Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia-in-adults\" class=\"medical medical_review\">Treatment of relapsed or refractory acute lymphoblastic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-myeloid-leukemia\" class=\"medical medical_review\">Treatment of relapsed or refractory acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-multiple-myeloma\" class=\"medical medical_review\">Treatment of relapsed or refractory multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory peripheral T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-protocols-for-multiple-myeloma\" class=\"medical medical_review\">Treatment protocols for multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors</a></li></ul></div></div>","javascript":null}